Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 1 -  
CLINICAL TRIAL PROTOCOL : V72203  
 
Protocol Number:  V72203  
Protocol Date:   FINAL / 09 July 2018 
   Amendment 1/ 29 October 2018  (version 6. 0) 
   Amendment 2/ 17 January 2019 (version 7.0)  
   Amendment 3/ 22 February 2019 (version 8.0)  
   Amendment 4/ 30 October 2019  (version 9.0)  
Protocol Title:  Randomized, double -blind, placebo controlled , dose finding Phase 2 
study comparing oral daily dosing of VERU -944 after a week of 
loading (daily dosing) with placebo to ameliorate the vasomotor 
symptoms resulting from androgen deprivation therapy in men with 
advanced prostate cancer  
IND number:   134105  
EudraCT number:   
Clinical Phase:  2 
Study Sponsor: Veru Inc. 
48 NW 25th St 
Suite 102 
Miami, FL 33127 Telephone: (305) 509-6986 
 
CONFIDENTIAL  
This document is a c onfidential communication of Veru  Inc. All information and data 
contained within this document is confidential. Acceptance of this document constitutes the 
agreement by the recipient that no information contained herein may be divulged or disclosed 
to third parties without prior written a pproval.  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 2 - TABLE OF CONTENTS  
1.0 LIST OF ABBREVIATIONS  ................................ ................................ ...... 5 
2.0 PROTOCOL SUMMARY  ................................ ................................ ..........  7 
3.0 INTRODUCTION  ................................ ................................ ....................  10 
3.1 Background  ................................ ................................ ...............................  10 
3.2 Target Indication and Pharmacologic Activity  ................................ ...............  10 
3.3 Study Rationale  ................................ ................................ ..........................  12 
4.0 STUDY OBJECTIVES  ................................ ................................ .............  13 
4.1 Primary Objective  ................................ ................................ ......................  13 
4.2 Secondary Objectives  ................................ ................................ .................  13 
4.3 Exploratory Objectives ................................ ................................ ................  13 
4.4 Safety Objective  ................................ ................................ .........................  13 
5.0 STUDY DESIGN  ................................ ................................ ......................  13 
5.1 Treatment Groups and Allocation of Subjects  ................................ ................  13 
5.2 Study Duration  ................................ ................................ ...........................  14 
5.3 Efficacy Endpoints  ................................ ................................ .....................  14 
5.3.1  Primary Endpoints  ................................ ................................ ......................  14 
5.3.2  Secondary Endpoints  ................................ ................................ ..................  14 
5.3.3  Exploratory Endpoints  ................................ ................................ ................  14 
6.0 SUBJECT POPULATION  ................................ ................................ ........  15 
6.1 Number of Subjects  ................................ ................................ ....................  15 
6.2 Selection Criteria  ................................ ................................ ........................  15 
6.2.1  Inclusion Criteria  ................................ ................................ ........................  15 
6.2.2  Exclusion Criteria  ................................ ................................ .......................  16 
7.0 STUDY MEDICATION  ................................ ................................ ............  17 
7.1 Enrollment and Blinding  ................................ ................................ .............  17 
7.2 Drug Supply  ................................ ................................ ..............................  17 
7.2.1  Placebo Capsules  ................................ ................................ ........................  17 
7.2.2  VERU -944 Capsules, 10, 50 and 100 mg  ................................ ......................  17 
7.2.3  Drug Dose Justification  ................................ ................................ ...............  18 
7.2.4  Drug Accountability  ................................ ................................ ...................  20 
7.3 Drug Administration  ................................ ................................ ...................  20 
8.0 STUDY PROCEDURES  ................................ ................................ ...........  21 
8.1 Clinic Visits  ................................ ................................ ...............................  21 
8.2 Screening  ................................ ................................ ................................ .. 21 
8.3 Enrollment  ................................ ................................ ................................ . 23 
8.4 Day 1 Visit  ................................ ................................ ................................  23 
8.5 Day 14 Visit  ................................ ................................ ..............................  24 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 3 - 8.6 Day 30 and Day 60 Visit  ................................ ................................ .............  24 
8.7 Day 84 Visit (End of Study Visit) ................................ ................................ . 25 
8.8 Follow -up Visit  ................................ ................................ ..........................  26 
8.9 Pharmacokinetic Sampling  ................................ ................................ ..........  26 
8.9.1  Blood Samples  ................................ ................................ ...........................  26 
8.9.2  Plasm a Sample Labels  ................................ ................................ ................  26 
8.10  Rules for Subjects that Become at High Risk for the Development of Venous 
Thromboembolic Events during the Study  ................................ .....................  27 
8.11  Subject Stopping Rules  ................................ ................................ ...............  27 
8.12  Early  Discontinuation of Study Treatment  ................................ .....................  28 
8.13  Adverse Events  ................................ ................................ ..........................  28 
8.13.1  Intensity of Adverse Events  ................................ ................................ .........  29 
8.13.2  Test Medication Causality  ................................ ................................ ...........  30 
8.13.3  Serious Adver se Events  ................................ ................................ ...............  31 
8.13.4  Initial Reports  ................................ ................................ ............................  31 
8.13.5  Precautions  ................................ ................................ ................................  32 
8.13.6  Reporting of Adverse Events Associated with Study Drug Overdose, Misuse, 
Abuse or Medication Error  ................................ ................................ ..........  32 
8.14  Concomitant Medications and Concomitant Therapies  ................................ ... 32 
8.15  Prohibited  Medications  ................................ ................................ ...............  33 
8.16  Withdrawal  of Subjects  ................................ ................................ ...............  33 
9.0 STATISTICAL ANALYSIS  ................................ ................................ ...... 34 
9.1 Sample Size Calculation  ................................ ................................ ..............  34 
9.2 Populations  ................................ ................................ ................................  34 
9.3 Efficacy Analyses  ................................ ................................ .......................  34 
9.3.1  Primary Analyses  ................................ ................................ .......................  35 
9.3.1.1  Hot Flash  Frequency, Week 6 (Day 42)  ................................ ........................  35 
9.3.2  Secondary Analyses  ................................ ................................ ....................  36 
9.3.2.1  Hot Flash Frequency (Weeks 4, 8, 10 and 12) and Severity (Weeks 4, 6, 8, 10, and 
12) ................................ ................................ ................................ ............  36 
9.3.2.2  Bone Turnover Mark ers ................................ ................................ ..............  37 
9.3.3  Exploratory Analyses  ................................ ................................ ..................  37 
9.3.3.1  Serum PSA  ................................ ................................ ................................  37 
9.3.3.2  Change in Serum Total and Free Testosterone Concentration  ..........................  37 
9.3.3.3  Serum SHBG  ................................ ................................ .............................  37 
9.3.3.4  Pharmacokinetic Assessments  ................................ ................................ ...... 37 
9.3.4  Safety Analysis  ................................ ................................ ..........................  38 
9.3.4.1  Data Safety Monitoring Board  ................................ ................................ ..... 38 
10.0  ADMINISTRATION PROCEDURES  ................................ .......................  38 
10.1  Study Conduct and Compliance  ................................ ................................ ... 38 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 4 - 10.2  Informed Consent  ................................ ................................ .......................  39 
10.3  Protocol Amendments  ................................ ................................ .................  39 
10.4  Protocol Deviations  ................................ ................................ ....................  40 
10.5  Data Handling and Recordkee ping ................................ ...............................  40 
10.5.1  Data Handling  ................................ ................................ ............................  40 
10.5.2  Data Entry  ................................ ................................ ................................ . 41 
10.5.3  Medical Information Coding  ................................ ................................ ........  41 
10.5.4  Data Validation  ................................ ................................ ..........................  41 
10.5.5  Record Keeping  ................................ ................................ .........................  41 
10.6  Data Quality  ................................ ................................ ..............................  41 
10.7  Regulatory Approval  ................................ ................................ ..................  42 
10.8  Publication Policy  ................................ ................................ ......................  42 
10.9  Clinical Study Report  ................................ ................................ ..................  43 
10.10  Contractual and Financial Details  ................................ ................................ . 43 
10.11  Insurance and Indemnity  ................................ ................................ .............  43 
11.0  REFERENCES  ................................ ................................ .........................  43 
12.0  APPENDICES  ................................ ................................ ..........................  47 
12.1  Appendix A: Clinical Laboratory Tests (central laboratory)  ............................  47 
12.2  Appendix B: Schedule of Study Evaluationse ................................ ................  48 
11.3  Appendix C: Hot Flash Assessments  ................................ ............................  49 
12.3  Appendix  D: Caprini Venous Thromboembolism Risk Factor Asse ssment  ....... 50 
 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 5 - 1.0 LIST OF ABBREVIATIONS  
ADT  Androgen deprivation therapy 
AE Adverse event 
ALT  Alanine aminotransferase 
AST  Aspartate aminotransferase 
BUN Blood urea nitrogen 
CTX C-Telopeptide cross-links of type I collagen 
eCRF Electronic Case report form 
DHEA  Dehydroepiandrosterone 
DHEAS  Dehydroepiandrosterone sulfate 
DHT  Dihydrotestosterone 
ECOG Eastern Cooperative Oncology Group 
ER Estrogen receptor 
ES Elastic stockings 
FXaI  Factor X inhibitor 
GCP Good clinical practice 
GGT  Gamma -glutamyl transferase 
hERG Human ether-à-go-go related gene  
IEC Independent ethics committee 
IMP Investigational medicinal product 
IPC Intermittent pneumatic compression 
IRB Institutional review board 
IUD Intrauterine device 
IUS Intrauterine system 
IWRS 
LDH  Interactive Web Response System 
Lactate dehydrogenase 
LDL  Low density lipoprotein 
LDUH  Low dose unfractionated heparin 
LH Luteinizing hormone 
LHRH Luteinizing hormone releasing hormone 
LMWH  Low molecular weight heparin 
MedDRA 
MRI Medical dictionary of regulatory activities 
Magnetic resonance imaging 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 6 - MMRM Mixed Models Repeated Measures  
NSAID Nonsteroidal anti-inflammatory drug 
OTC  Over the Counter 
PCWG2 Prostate Cancer Working Group 2 
PRN Pro re nata  ± As Needed 
PSA Prostate s pecific antigen 
SAE  Serious adverse event 
SHBG Sex hormone binding globulin 
SRE Skeletal related event 
T½  Plasma concentration elimination h alf-life 
TNM  Tumor staging, T = primary tumor, N = lymph nodes, M = 
distant metastases  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 7 - 2.0 PROTOCOL SUMMARY  
Study 
Number: 
  
V72203 
Title: Randomized, double-blind, placebo controlled, dose finding Phase 2 study 
comparing oral daily dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the vasomotor symptoms resulting from androgen deprivation therapy in men with advanced prostate cancer 
 
Primary 
Objective:  
 
 
 
    Secondary 
Objectives: 
   
 
 
 
 
 
  
 
Exploratory 
Objectives: 
  
 
 
 
 
Safety 
Objective:  
To determine an effective dose of VERU-944 (from among 10 mg, 50 mg, and possibly 100 mg PO q day), after a loading dose, for the treatment of vasomotor symptoms commonly known as hot flashes by assessing its effect on: 
 
1. the frequency of moderate to severe hot flashes at week 6 
  
 To assess the effect of VERU-944 on: 
1. the severity of moderate to severe hot flashes at week 6 
2. the frequency of moderate to severe hot flashes at week 8 
3. the frequency of moderate to severe hot flashes at week 10 
4. the frequency of moderate to severe hot flashes at week 12 
5. the severity of moderate to severe hot flashes at week 8 
6. the severity of moderate to severe hot flashes at week 10 
7. the severity of moderate to severe hot flashes at week 12 
8. the frequency of moderate to severe hot flashes at week 4 
9. the severity of moderate to severe hot flashes at week 4 
10. bone turnover markers 
To assess the effect of VERU-944 on: 
1. serum PSA concentrations 
 
2. serum total and free testosterone concentrations 
 
3. serum SHBG concentrations 
 To assess the safety and tolerability of VERU-944 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 8 - Design: This study is a multicenter, randomized, double-blind, placebo controlled, 
dose finding study of VERU-944 to treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT. The study will be conducted as a staged study with Stage 1 being a three-arm evaluation of placebo, 10 mg and 50 mg of VERU-944. When all subjects have completed Week 6 (Day 42) of dosing, an evaluation of the efficacy of the doses administered in Stage 1 will be made (safety will be assessed in a blinded review) and Stage 2, a two-arm evaluation of placebo and 100 mg VERU-944 may be initiated. Stage 1 of the study will have three arms (placebo, 10 mg VERU-944, and 50 mg VERU-944) and Stage 2 of the study will have two arms (placebo and 100 mg VERU-944) with 
approximately 30 subjects per arm. The subjects participating in the study 
will have advanced prostate cancer and will be undergoing androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone (LHRH) therapy (agonist or antagonist) for at least the three months prior to randomization and be experiencing regular moderate to severe hot flashes while on ADT.  Subjects w ill all continue to receive ADT and will 
be randomized to receive, for the first four days, a loading dose followed by daily doses of placebo or VERU-944 (10 mg, 50 mg or 100 mg) orally for a total period of 12 weeks.   
Subjects: Approximately, ninety ( 90) subjects will be randomized into Stage 1 of this 
study and approximately 60 subjects are planned to be randomized into 
Stage 2 of this study. Subjects with advanced prostate cancer who have 
experienced moderate to severe vasomotor symptoms (hot flashes) for at least one month prior to study entry will be enrolled.  Subjects must have been maintained on ADT with an LHRH agonist or antagonist for at least the 3 months prior to randomization will be screened for the study and if these subjects meet the other inclusion/exclusion criteria, will be randomized into the study.   
Treatments: Subjects will be maintained on ADT with an LHRH agonist or antagonist 
while on the study.  In addition to ADT, each subject will be orally administered either placebo, 10, or 50 mg of VERU-944 daily after they have completed a four day loading dose as outlined in Section 7.3 in Stage 1 of the study. Each subject in Stage 2 of the study will receive either 
placebo or 100 mg of VERU-944 daily after they have completed a four 
day loading dose as outlined in Section 7.3.  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 9 - Procedures: 
 Potential study participants will undergo a series of screening evaluations 
within 28 days prior to randomization.  Subjects who give written informed consent and satisfy the selection criteria will be enrolled into the study.   
The frequency and severity of hot flashes will be recorded daily beginning 
with screening and through week 12 (Day 84). Assessments of serum total 
and free testosterone, serum SHBG and serum PSA will be made at baseline (Day 1), Days 30, 60 and 84.  Bone turnover markers will be assessed at baseline (Day 1) and Day 84.   
Safety evaluations including assessment of adverse events, serum PSA, 
periodic monitoring of vital signs, 12-lead electrocardiogram (single) and 
clinical laboratory results (including hematology, serum chemistry (including LDH) will be conducted at every visit. 
Patients that have been previously screened for this study and could not 
complete screening for reasons other than not meeting the inclusion and exclusion criteria, may be rescreened into the study. Laboratory testing conducted under this protocol (Appendix A) within 45 days prior to randomization into this study, may be used as the baseline laboratory values for this study and repeat laboratory testing is not required unless new coadministered medication(s) has been started, unless the investigator determines that retesting is warranted. 
Stage 2 
dosing 
evaluation: After the last subject has completed Day 42 of Stage 1, an unblinded 
assessment of the Week 6 (Day 42) hot flashes frequency (primary endpoint), hot flash severity (first secondary endpoint),and a blinded assessment of safety of VERU-944 will be conducted. 
If an effective dose of VERU-944 has been identified in Stage 1, Sponsor 
reserves the right to not initiate Stage 2 of this protocol. 
If an unacceptable safety profile is observed in Stage 1, Sponsor reserves 
the right to not initiate Stage 2 of this protocol. 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 10 - 3.0 INTRODUCTION  
3.1 Background  
Veru Inc. is develop ing VERU -944 (cis-clomiphene ), a nonsteroidal estrogen , as a hormonal 
therapy for the alleviation of vasomotor symptoms, commonly known as hot flashes in men 
undergoing ADT. Cis -clomiphene is one of two geometric isomers of clomiphene, which is 
approved as Clomid® (clomiphene citrate oral capsules , 50 mg; NDA  016131; Sanofi Aventis 
US) for the treatment of ovulatory dysfunction in women desiring pregnancy. While trans -
clomiphene is anti -estrogenic, cis -clomiphene is an estrogen agonist at pharmacologic 
concentrations (Turner et al., 1998;  Fitzpatrick et al., 1 999; Kaminets ky et al., 2013 ). 
Furthermore, cis -clomiphene has a half -life of 5±7 days (Mikkelson et al., 1986; Mür dter et 
al., 2012 ). VERU -944 is expected to be effective and safe in men with prostate cancer 
undergoing ADT  based on the established efficac y of low dose  estrogens  in the treatment of  
vasomotor symptoms  (hot flashes ) and safety of off-label clomiphene use for male infertility . 
3.2 Target Indication and Pharmacologic Activity  
Introduction  
Prostate cancer is the most common cancer in men with over 160 ,000 new cases expected  in 
2017  (American Cancer Society. Cancer Facts & Figures 2017 ).  As advanced prostate cancer 
is hormone sensitive, androgen deprivation therapy (ADT) is the standard of c are for patients 
with metastatic or locally advanced prostate cancer, either alone or in combination with other 
drug treatments or radiation (National Comprehensive Cancer Network, 2016). The main 
objective of ADT is to lower the serum testosterone level t o castrate level of approximately 
1.7 nmol/L (< 50 ng/dL) (Djavan et al., 2012) . ADT is usually achieved either by surgical 
orchiectomy (castration) or by medically administering LHRH (luteinizing hormone  releasing 
hormone) agonists and antagonists.   
One o f the main side effects of low testosterone levels in  men is vasomotor symptoms, 
commonly known as  hot flashes.  Hot flashes are experienced by about 75% of men receiving 
ADT  (Holzbeierlein et al., 2004 ) aQd aUe a VigQificaQW cRmSRQeQW iQ meQ¶V perceptio n of their 
quality of life (Holzbeierlein et al., 2004 ).  One study found 38% of men who had experienced 
hot flashes over the past four wee ks were distressed about them (Holzbeierlein et al., 2004 ).  
These hot flashes can have a long duration.  Fo r example , in men experiencing hot flashes 
while on ADT, 70% of them continued to experience them five years later ( Karling 1994).  
Men describe their experience of hot flashes with physical as well as emotional descriptors 
(Isbarn et al., 2008 ).  Up to 80% of  men have described hot flashes that range from mild to 
very severe, lasting up to 30 minutes and accompanied by feelings of anxiety, irritability and 
being out of control.  (Schow 1998 ). Hot flashes for men, as for women, often require some 
sort of act ion such as changing clothes or ta king a shower ( Isbarn et al., 2008 ). Hot flashes in 
men who have advanced prostate cancer being treated by ADT  have detrimental effects on 
overall quality of life  such that  cancer -related distress caused by hot flashes ar e a contributing 
factor in the discontinuation of ADT ( Engstrom, 2008; Ulloa et al., 2009; Frisk, 2010).  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 11 - The precise mechanism of hot flashes in men is not fully understood, but appears to be similar 
to postmenopausal hot flashes in women. Studies in postme nopausal women and women 
undergoing breast cancer treatment who experience hot flashes have shown that abrupt 
withdrawal of sex hormones leads to a dysfunctional hypothalamic thermoregulation resulting 
in vasomotor flushing (Kaplan and Mahon, 2014 ). In wom en, hormones (usually estrogen 
combined with progesterone), selective serotonin reuptake inhibitors (SSRIs) and serotonin -
noradrenalin reuptake inhibitors (SNRIs), clonidine, and gabapentin have been effect ive in 
treating hot flashes. Similar treatments ha ve been attempted in men with inconsistent activity ; 
overall, hormonal treatments (cyproterone and medroxyprogesterone) are generally thought to 
be more effective than non -hormonal treatments at reducing hot flashes in men on ADT 
(Loprinzi  et al., 1994; Frisk, 2010; Irani et al., 2010; Vitolins et al., 2013) . Hot flashes in men 
on ADT are typically treated  by off -label treatments such as  an SSRI, whereas  hormones such 
as estrogen and megestrol are reserved for refractory cases (Smith and Cr awford, 2017) . 
Hot Flash Treatment for Men  
There are no approved therapies for the treatment of moderate to severe vasomotor symptoms 
in men with advanced prostate cancer on AD T. There have been few placebo controlled, 
multicenter studies evaluating possib le drug interventions for hot flashes these  men. 
Megestrol acetate, 2 0 mg twice a day (Loprinzi et al., 1994 ), depo medroxyprogesterone 400 
mg IM (Brosman S 1995 ), and venlafaxine 12.5 mg twice a day  has been investigated as a 
tool to address hot flashes in  men (Loprinzi et al., 1999 ).  A very small randomized trial was 
completed with 12 men after orchiectomy with cyproterone acetate (100 mg three times a 
day) which a ppeared to reduce hot flashes (Eaton and McGuire, 1993 ).  In  addition to 
hormonal approaches , in women, the norepinephrine reuptake inhibitor, venlafaxine , has been 
studied and shown to be  an effective non -horm onal treatment for hot flashes ( Evans et al., 
2005 ) although there is no  evidence that this approach will work in men .  
Another drug that has received some pilot testing , specifically in men , is sertraline as reporte d 
in a series of case studies (Roth and Scher 1997 ).  Five men who were being treated with 
androgen ablation therapy for prostate cancer exhibited symptoms of hot flashes, s ymptom 
distress, trouble sleeping, worsening mood, fatigue and illness concerns.  Patients were treated 
with sertraline, starting with 25 mg daily, and titrated up to 100 or 150 mg daily.  From these 
five cases, it appeared that improvement in hot flashes was not experienced until the dose was 
at least 50 mg daily and side effects were experienced at a dose of 150 mg daily.  Specific 
reductions in hot flashes were not provided for every case, but one man experienced a 75 % 
reduction in hot flashes while ano ther experienced a 50% reduction.  In addition to hot flash 
reduction, the author reports improve ment in mood and irritability (Roth and Scher 1997 ).  
Doses from 50 mg to 100 mg appeared to be tolerated very well in this small group of cases.  
Gabapentin  for the treatment of hot flashes  
To date, there has only been one  placebo -controlled, Phase 3 study of a n agent to control hot 
flashes in men with prostate cancer on ADT.  This study, albeit non -regulatory, investigated 
the anti -seizure medic ation, gabapenti n. In this trial , men with bothersome hot flashes as 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 12 - defined as the o ccurrence of at least 14 times per week , were evaluated and of sufficient  
severity to make the patient desire therapeutic intervention, with the hot flashes being present 
for at least 1 month before study entry .  The study duration was four weeks and during this 
time, the patients on the highest gabapentin dose arm (900 mg/day)  demonstrated a significant 
decrease in hot flash frequency (p=0.02) and a trend towards lower scores (p=0.10) ( Loprinzi 
2009 ).  In a continuation phase of this study, those effects were maintained (Moraska et al., 
2007 ). Although these results were promis ing, gabapentin is not widely used for the treatment 
of hot flashes in this male population and the unmet medical need remains.  
 
Estrogens for the treatment of hot flashes in men with advanced prostate cancer on ADT  
 
As stated briefly above, vasomotor sympto ms (hot flashes) occur in a majority of men 
receiving ADT for advanced pros tate cancer.  Since decreasing estrogen levels as a result of 
the ADT are  a contributing  cause of the hot flashes, the off -label use of estrogenic compounds 
have  historically been used.  For example, low doses of diethylstilbestrol (0.25 mg/day) 
appears to have efficacy but can result in significant breast swelling and tenderness along with 
an increase in cardiovascular side effects  (Smith JA 1994; Smith J A 1996 ; Glashan 1981 ).  
Transdermal estrogen patches are another route of off -label administration of estrogens for 
this indication.  In a study of twelve men with moderate to severe hot flashes who were 
randomized to receive either low dose (0.05 mg) of high dose  (0.10  mg) estrogen twice 
weekly for four weeks.  Although no placebo group was included in this study, a significant 
reduction in the severity and frequency of hot flashes was observed in the high dose arm and 
in severity only in the low dose arm ( Gerber  2000 ).   
 
In conclusion , while  the off-label use of estrogens appear s to have benefit for the treatment of 
hot flashes in men with advanced prostate cancer , the type of most efficacious estrogen or 
estrogen preparation as well as dosing route or schedule i s not known. Furthermore, the 
potential for safety issues with potent steroidal estrogens remains a significant limitation to 
their clinical utility.  These published data support the evaluation of VERU -944 to determine 
the optimal dose for efficacy and sa fety of a nonsteroidal estrogen to treat hot flashes in men 
with advanced prostate cancer on ADT.  
3.3 Study Rationale  
Veru is evaluating cis-clomiphene  (zuclomiphene) , a nonsteriodal estrogen,  as a horm onal 
therapy for the amelioration  of hot flashes in men undergoing ADT  for advanced prostate 
cancer . Cis-clomiphene is one of two geometric isomers of clomiphene, which is approved as 
Clomid® (clomiphene citrate oral tablets, 50 mg; NDA 016131; Sanofi Aventis US) for the 
treatment of ovul atory dysfunction in women desiring pregnancy. While trans -clomiphene is 
anti-estrogenic, cis -clomiphene is an estrogen agonist at pharmacologic concentrations 
(Turner et al., 1998; Fitzpatrick et al., 1999; Kaminetsky et al., 2013;  Section 7.4.1.1). 
Furth ermore, cis -clomiphene has a half -life of 5±7 days (Mikkelson et al., 1986; Mürdter et 
al., 2012). VERU -944 is expected to be effective and safe in men with prostate cancer 
undergoing ADT based on the established efficacy of low dose  estrogens in the treat ment of 
vasomotor symptoms (hot flashes) and safety of off -label clomiphene use for male infertility.   
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 13 - 4.0 STUDY OBJECTIVES  
4.1 Primary Objective  
To determine an effective dose of VERU -944 (from among 10 mg, 50 mg, and possibly  100 
mg PO q day),  after a loading d ose, for the treatment of vasomotor symptoms commonly 
known as hot flashes by assessing its effect on :  
1. the frequency of moderate to severe hot flashes at week 6 
2.  
4.2 Secondary Objective s 
To assess the effect of VERU -944 on:  
1. the severity of moderate to severe hot flashes at week 6  
2. the frequency of moderate to severe hot flashes  at week 8  
3. the frequency of moderate to severe hot flashes  at week 10  
4. the frequency of moderate to severe hot flashes  at week 12  
5. the severity of moderate to severe hot flashes at week 8  
6. the severity of moderate to severe hot flashes at week 10  
7. the severity of moderate to severe hot f lashes at week 12  
8. the frequency of moderate to severe hot flashes  at week 4  
9. the severity of moderate to severe hot flashes at week 4  
10. bone turnover markers  
 
4.3 Exploratory Objectives  
To assess the effect of VERU -944 on:  
1. serum PSA concentrations  
 
2. serum total and free testosterone concentrations  
 
3. serum SHBG concentrations  
4.4 Safety Objective  
To assess the safety and tolerability of VERU -944 
5.0 STUDY DESIGN  
5.1 Treatment Groups and Allocation of Subjects  
This randomized, multicenter, double blind , placebo controlled clinical study consists of three  
treatment arms  along with a plac ebo arm with approximately thirty  (30) subjects enrolled in 
each of three treatment  arms in a 1:1:1 fashion (placebo, 10 and 50 mg) in Stage 1 and 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 14 - approximately thirty (30)  subjects randomized in a 1:1 fashion to each of two treatment arms 
(placebo and 100 mg) in Stage 2 .  Each subject will be randomized , and a fter a four -day daily 
loading dose , outlined in Section 7 .3, w ill receive  either  placebo,  10 mg VERU -944 or 50 mg 
VERU -944 daily in Stage 1 and either placebo  or 100 mg VERU -944 daily  in Stage 2 .  
5.2 Study Duration  
The study will require  that each subject receive a loading dose followed by a daily  oral dose 
of placebo, 10  mg VERU -944, 50 mg VERU -944 or 100 mg VERU -944 for 12 weeks ( 84 
days).   
5.3 Efficacy Endpoints  
5.3.1 Primary E ndpoint s 
Patients will record frequency and severity of hot flashes using an electronic diary (eDiary) at 
home to ensure attributable, time stamped data collection in an unsupervised environment.   
This instrument will be used to assess the:  
1. Percentage change in f requency  of modera te to severe vasomotor symptoms from baseline 
to W eek 6 (Day 42)  
5.3.2 Secondary E ndpoints  
1. Percentage change in severity of vasomotor symptoms from baseline to Weeks 6 (Day 42)  
2. Percentage  change in frequency of moderate to severe vasomotor symptoms from baseline 
to Week 8 (Day 56)  
3. Percentage  change in frequency of moderate to severe vasomotor symptoms from baseline 
to Week 10 (Day 70)  
4. Percentage  change in frequency of moderate to severe vasomotor symptoms from baseline 
to Week 12 (Day 84)  
5. Percentage  change in severity of vasomotor symptoms from baseline to Week 8 (Day 56)  
6. Percentage  change in severity of vasomotor symptoms from baseline to Week 1 0 (Day 70)  
7. Percentage  change in severity of vasomotor symptoms from baseline to Week 12 (Day 84)  
8. Percentage  change in frequency of moderate to severe vasomotor symptoms from baseline 
to Week 4 (Day 28)  
9. Percentage  change in severity of vasomotor symptom s from baseline to Week 4 (Day 28)  
10. Percentage c hange in b one turnover marker concentrations  at Day 84 compared with  
baseline  
5.3.3 Exploratory E ndpoints  
1.  Percentage c hange in s erum PSA concentrations  at Days 30, 60, and 84  compared with 
baseline  
 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 15 - 2. Percentage c hange in s erum total and free testosterone concentrations  at Days 30, 60, and 
84 compared with baseline  
 
3. Percentage c hange in s erum SHBG concentrations  at Days 30, 60, and 84  compared with 
baseline  
6.0 SUBJECT POPULATION  
6.1 Number of Subjects  
Approximately ninety  (90) subjects will be enrolled in to Stage 1 of  the study, with 
approximately thirty  (30) subjects in each of three treatment  arms  (placebo, 10 and 50 mg). 
Approximately sixty (60) subjects will be enrolled into Stage 2 of the study, with 
approximately thirty (30) subjects in each of two treatment arms (placebo and 100 mg) .  
6.2 Selection Criteria  
6.2.1 Inclusion C riteria  
Subject s accepted for this study must:  
1. Be over  18 years  of age  
2. Be able to communicate effectively with the study personnel  
3. Have  histologically confirmed prostate cancer  
4. Have been treated with an LHRH agonist or LHRH antagonist for at least the 2 months  
prior to randomization  
5. Be continued on an LHRH agonist or LHRH antagonist throughout this study  (must be 
continuous therapy)  
6. Have experienced hot flashes for at least one month prior to study entry  
7. Have  moderate or severe vasomotor symptoms (hot flashes)  (defined as a m inimum of 4  
moderate to severe hot flashes per day or 12 per week at baseline ) 
8. ECOG performance status of 0 to 2  
9. Be willing to uses electronic data capture for the relevant medical events  
x Must be at least 80% compliant during the screening period  (for the  14 
contiguous day  hot flash  assessment that is required during screening)   
10. Subjects must agree to use acceptable methods of contraception  
x If their female partners are pregnant or lactating , acceptable methods of 
contraception from the time of the first admini stration of study medication until 
6 months following administration of the last dose of study medication  must be 
used. Acceptable methods are: Condom used with spermicidal 
foam/gel/film/cream/suppository . If the subject has undergone surgical 
sterilizatio n (vasectomy with documentation of azospermia) , a condom with 
spermicidal foam/gel/film/cr eam/suppository should be used  
x If Whe male VXbjecW¶V SaUWQeU cRXld becRme SUegQaQW , use acceptable methods of 
contraception from the time of the first administration of study medication until 
6 months following administration of the last dose of study medication. 
Acceptable methods of contraception are as follows: Condom with spermicidal 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 16 - foam/gel/film/cream/suppository [i.e. , barrier method of contraception] , surgical 
sterilization (vasectomy with documentation of azospermia) and a barrier 
method {condom used with spermicidal foam/gel/film/cream/suppository} , the 
female partner uses oral co ntraceptives (combination estrogen/progesterone 
pills), injectable progesterone or subdermal implants and a barrier method 
(condom used with spermicidal fo am/gel/film/cream/suppository ) 
x If the female partner has undergone documented tubal ligation (female 
sterilization ), a barrier method (condom used with spermicidal 
foam/gel/film/cream/su ppository ) should also be used  
x If the female partner has undergone documented placement of an intrauterine 
device (IUD) or intrauterine system (IUS) , a barrier method (condom with 
spermicidal foam/gel/film/cream/suppository ) should also be used  
11. Subject is willing to comply with the requirements of the protocol through the end of the 
study  
6.2.2 Exclusion C riteria  
Any of the following conditions are caus e for exclusion from the st udy: 
1. Have a serum total testosterone concentration > 50 ng/dL  at screening  
2. Known hypersensitivity or allergy to estrogen or estrogen like drugs  
3. Any disease or condition (medical or surgical) which might compromise the hematologic, 
cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic, or central nervous 
system; or other conditions that may interfere with the absorption, distribution, 
metabolism or excretion of study drug, or would place the subject at increased risk  
4. Subjects with a personal h istory of abnormal blood clotting or thrombotic disease, 
including venous or arterial thrombotic events such as  a history of stroke, deep vein 
thrombosis (DVT) , and/or pulmonary embolus (PE)  
5. Any subjects , as determined by a central laboratory,  that have a : 
x Factor V Leiden gene mutation   
x Prothrombin gene mutation  
6. Uncontrolled s ymptomatic congestive heart failure (NYHA Class III ± IV), unstable 
angina pectoris, cardiac arrhythmia , or uncontrolled  atrial fibrillation  
7. History of MI in the past 12 months  
8. The presence of consistently abnormal laboratory values which are considered clinically 
significant. In addition, any subject with liver enzymes ( ALT  or AST ) above 2 times the 
upper limit of normal, total bilirubin above 2 times the upper limit of normal , or serum 
creatinine above 1.5 times the upper limit of normal  will NOT be admitted to the study  
9. Received an investigational drug within a period of 90 days prior to enroll ment in the 
study  
10. Received the study medication (VERU -944) previously  
11. Have previously taken within 3 months prior to screening or are c urrently taking 
dieth ylstilbestrol, other estrogens ; 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 17 - 12. Currently taking gabapentin , estrogen, diethylstilbestrol, medroxyprogesterone acetate , 
clomiphene, selective serotonin reuptake inhibitors  (SSRIs) , other treatment s for hot 
flashes  
13. Recent hospitalization  for more than 24 hours  (within 30 days of screening)  
14. Recent surgery (within 30 days of screening)  
15. Have been previously diagnosed or treat ed for active  cancer  (other than prostate cancer or 
non-melanoma skin cancer)  within the previous five  years  
16. Have a BMI > 40 
17. Have been randomized into Stage 1 of this protocol  
7.0 STUDY MEDICATION  
7.1 Enrollment and Blinding  
Stage 1 of the study will be a randomized (1:1:1) double blind, placebo controlled  study  with 
approximately thirty  (30) subjects  in each of the three  treatment arms :  Subjects will be 
randomized (1:1:1)  to rec eive oral doses of placebo, 10  mg VERU -944, or 50 mg VERU -944 
daily for 12 weeks . 
Stage 2 of the study will be a randomized (1:1) double blind, placebo controlled study  with 
approximately thirty (30) subjects in each of the two treatment arms:  Subjects will be 
randomized (1:1) to receive oral doses of placebo or 100 mg VERU -944 daily for 12 weeks  
An emergency code break will be available to the investigator / pharmacist / investigational 
drug storage manager. This code break option in IWRS may only be disclosed in emergency 
situations when the identity of the trial drug must be k nown to the investigator in order to 
provide appropriate medical treatment or if required to assure safety of trial participants. If the 
code break for a patient is opened, the sponsor and CRO will be informed immediately via 
IWRS notification. The reason for the IWRS unblinding of the subject must be documented 
on the appropriate eCRF page along with the date and the initials of the person who broke the 
code.  
7.2 Drug Supply  
7.2.1 Placebo Capsules  
Placebo capsules  are formulated with standard phar maceutical excipients, such as 
pregelatinized starch and/or lactose m onohydrate  and will be supplied in a capsule that 
matches the VERU -944 capsules.  The placebo  should be stored at room temperature, 15°C to 
25°C (59°F to 77°F) . 
7.2.2 VERU -944 Capsules , 10, 50 and 100 mg 
VERU -944 capsules , 10, 50 and 100 mg, are formulated with micronized VERU -944 drug 
substance and  standard phar maceutical excipients, such as pregelatinized starch and/or lactose 
monohydrate . The study drug will be supplied in 30-day kits. The study drug should be stored  
at room temperature, 15°C to 25°C  (59°F to 77°F).  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 18 - 7.2.3 Drug Dose Justification  
The doses of VERU -944 (cis -clomiphene) selected in this dose finding study are 10, 50 and 
100 mg daily.  Support for the utilization of these doses results from publ ished studies as well 
as additional work that the Sponsor has performed.  
In mouse studies, 40 mg/kg/day cis -clomiphene for 90 days results in a significant reduction 
in testicular weight as well as testicular degeneration (Fontenot GK et al., BJUI Int, 11 7:344 -
350, 2016).  Using the FDA published guidance on conversion from animal studies to humans 
(FDA, Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult 
Healthy Volunteers), the 40 mg/kg dose is multiplied by 0.08 resulting in a n equivalent 
human dose of 3.25 mg/kg.  For an average weight adult (70 kg) this would correspond to 227 
mg.  In the same study, at 4 mg/kg/day there were no effects on testicular degeneration but 
seminal vesicle weights were somewhat reduced. This dose wo uld correspond to a 22.7 mg in 
humans.  From this study, it appears that the efficacious range for cis -clomiphene will be 
above 22.7 mg with a maximum of 227 mg.  
In a study in baboons, administration of 1.5 mg/kg for 12 days resulted in mild 
reduction of t otal serum T levels, an estrogenic signal (Fontenot, unpublished 2001).  
Utilizing the FDA conversion from a baboon to a human dose (multiplication by 0.54), 
in an average adult, this would correspond to 56.7 mg further supporting our proposed 
dose range f or the Phase 2 study.   
In ovariectomized female rats 3 mg/kg cis -clomiphene for 90 days results in the 
restoration of uterine weight to the pre -ovariectomized state similar to a 0.1 mg/kg 
dose of estradiol (Turner RT et al., Endo, 139:3712 -3720, 1997).  A  3 mg/kg dose in 
rats would correspond to 33.6 mg daily dose in an average human.   
When hypogonadal men were treated with 25 mg daily clomiphene citrate for 6 
weeks, the median steady state level of cis -clomiphene was 44.0 ng/ml (Helo S et al., 
BJUI Int 1 19:171 -176, 2017).  Assuming that clinically available clomiphene citrate 
contains 30% cis -clomiphene, that would equate to 7.5 mg daily cis -clomiphene 
resulting in these steady state levels.  Extrapolating the daily doses that will be used in 
this study, a 10 mg dose will result in steady state level of 59 ng/ml, a 50 mg dose 
would result in 293 ng/ml and a 100 mg dose would result in 1,173 ng/ml.   
In order to determine if these concentration ranges would result in estrogenic activity, 
in vitro assays wer e utilized.  In a transactivation assay, the effective concentration of 
cis-clomiphene app ears to be in the range of 1.2 PM which correspond to a level 717.6 
ng/ml.  Based upon the Helo 2017 study, this blood level would be achieved within 
the dose finding  range of 50 mg and 100 mg.  In a separate in vitro study utilizing a in 
a rat hypothalamic cell line they observed an EC 50 of cis -clomiphene of 100 nM  
corresponds to a level of 60 ng/ml (Fitzpatrick SL Endo 140:3928 -3937, 1999).  This 
cRQceQWUaWiRQ iV lRZeU WhaQ WhaW RbVeUYed iQ Whe SSRQVRU¶V VWXd\ aQd ma\ UeflecW, aV 
the authors point out, cell type specific differences.   
Low doses of estrogens have b een shown to ameliorate vasomotor symptoms (hot 
flashes) in men who underwent bilateral orchiectomy or on ADT for advanced 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 19 - prostate cancer.  A daily dose of 1 mg diethy lstilbestrol  (DES) over 12 weeks 
elimi nates the hot flashes in 86% of  these men (Atala A  et al., Urology, 1992).  
VERU -944 is 400X less potent of an estrogen as DES based on the transactivation in 
vitro study, but does have a much longer half -life supporting the selected dose range to 
evaluate the activity of VERU -944 for the treatment of hot  flashes in men who have 
advanced prostate cancer on ADT.  
VERU -944 is intended for daily maintenance dosing following a 4 -day loading period. 
Due to the relatively long half -life of cis -clomiphene, the loading doses were included 
in the protocol to shorten the time to steady -state cis -clomiphene plasma levels in 
order to determine whether that dose level will have efficacy at Day 28 to treat hot 
flashes, the primary endpoint of the proposed study. During the first 4 days of 
treatment, the subjects wi ll receive a loading dose that is determined by thei r 
maintenance dose (10, 50, or 1 00 mg). On day 1, subjects will take 5 times their 
maintenance dose at a single time; on days 2 ±4, subjects will take 3 times their 
maintenance dose at a single time.  
As me ntioned above, the rationale for the loading dose is to achieve steady state 
quickly to meet the Food and Drug Administration (FDA) requirement for the 
demonstration of efficacy at Day 28 of dosing (FDA Draft Guidance for Industry, 
2003: Estrogen and Estro gen/Progestin Drug Products to Treat Vasomotor Symptoms 
and Vulvar and Vaginal Atrophy Symptoms ± Recommendations for Clinical 
Evaluation). Based upon the published 14.2 ±33.4 day half -life of cis clomiphene 
(Szutu et al., 1989), without a loading dose, eva luation of efficacy as reflected by the 
steady state will not be achieved until after Day 28. Therefore, Veru has developed a 
dosing regimen for this study that inc ludes loading doses (see Table below ).  
Cis-clomiphene , as part of the FDA approved product Clomid , has been used in men 
for off -label acute and chronic indications with limited reported safety observations. 
However, in an ongoing nonclinical toxicology study of VERU -944 in rats and beagle 
dogs, preliminary indications are that the dose of VERU -944 required to treat hot 
flashes in men with prostate cancer on ADT is between 10 -50 mg  (data on file) . 
Moreover, at a high dose of cis -clomiphene of 20 mg/kg/day (a human equivalent dose 
of 667 mg in a 60 kg human) in male dogs, dose limiting toxicities h ave been 
observed. The dose limiting toxicities that have been observed include elevations in 
liver function tests (AST, ALT, alkaline phosphatase, GGT, and total bilirubin), 
weight loss and death. No significant toxicities have been observed in the ongoin g 
study in rats. Due to the preliminary information that suggests a dose of VERU -944 up 
to 50 mg per day will show efficacy and safety in the proposed indication, Protocol 
V72203  has been a mended  so that the 100 mg dose of VERU -944 will not be used 
until and unless the dose of 50 mg VERU -944 has been shown to not be effective for 
the proposed indication and an acceptable side effect profile is determined at the 
blinded placebo, 10 mg and 50 mg dos es of VERU -944 in Stage 1 .   
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 20 - 7.2.4 Drug A ccountability  
Patients should not take a replacement dose if a dose is missed. Study medication should not 
be taken more than once a day.  
The pharmacists or other site personnel as delegated by the Investigator are respon sible for 
accountability of all used and unused study drug supplies. A study drug dispensing log should 
be kept current and should contain the dates and quantities of drug dispensed to the subject, 
Whe VXbjecW¶V ideQWificaWiRQ (i.e., VXbjecW QXmbeU), Whe i nitials of the dispensing persons and the 
date and quantity of drug returned. Drug accountability and reconciliation should be assessed 
and performed at each outpatient visit. At the end of the study, a final study drug 
reconciliation statement will be ret rieved by the clinical monitor assigned to the site. Veru 
Inc., shall be immediately notified of any unexpected occurrences during the dispensing of 
study drug.  
7.3 Drug Administration  
Dosing should occur greater than (1) hour before or  greater than (1) hour a fter eating .  
Subjects will take the entire daily dose at on ce accordin g to the dosing schedule below.  
Subjects randomized to the placebo group will receive placebo capsules  daily. During the first 
four days of treatment, the subjects will receive a loading dose representing the dose arm that 
they have been randomized to.  On day one they will take five times their maintenance dose at 
a single time.  On days 2 -4 they will take 3 times their maintenance dose at a single time each 
day.  Upon completion of the loading dose (Days 1 -4), subjects in the 10  mg VERU -944 dose 
arm will receive one 10 mg capsule of VERU -944 daily .  Subjects in the 50 mg VERU -944 
dose arm will receive one 50 mg VERU -944 capsule  daily . Subjects in the 100 mg VERU -
944 dose arm will receive one 100 mg VERU -944 capsule  daily .  
Dosing Arm Day 1 Days 2-4 Days 5-84 
Stage 1 
Placebo (5 capsules) (3 capsules) (1 capsule) 
10 mg dosing arm 50 mg (5 capsules) 30 mg (3 capsules) 10 mg (1 capsule) 
50 mg dosing arm 250 mg (5 capsules) 150 mg (3 capsules) 50 mg (1 capsule) 
Stage 2 
Placebo (5 capsules) 3 (capsules) (1 capsule) 
100 mg dosing arm 500 mg (5 capsules) 300 mg (3 capsules) 100 mg (1 capsule) 
Amendment 4 of the protocol is implemented to change the primary endpoint from 
Week 4 (Day 28) to Week 6 (Day 42) due to the potential for some patients to have a 
longer T½ of cis -clomiphene up to 32 days. Patients with longer T½ will not reach 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 21 - steady stat e within the first 2 -3 weeks of dosing, even with the loading dose that is 
currently used in the protocol. Therefore, to adequately assess the effect of VERU -944 
on moderate to severe hot flashes at steady state, Week 6 (Day 42) is being named as 
the timep oint for the primary efficacy endpoint in this Phase 2 study.   
8.0 STUDY PROCEDURES  
A summary of clinical laboratory tests (Appendix A) and a flow chart describing study 
procedures (Appendix B ) can be found at the end of this document . 
8.1 Clinic Visits  
Potential study participants will visit the clinical research facility as ne eded for screening 
evaluations  in the 28 days prior to enrollment .  Subjects will have study related visits at Day 
1, Day 30, Day 60, and 84 .  A follow -up visit will be conducted approximately 30 days after 
the last dose.  
8.2 Screening  
Potential subjects will be screened for this study in the 28 days prior to enrollment . The 
following activities will be conducted at screening:  
1. Signed informed consent will be obtained prior to any study -specific procedures and a 
copy of the signed consent form will be given to the subject.  
2. Assess subject eligibility for inclusion into this study based on protocol 
inclusion/exclusion criteria.  
3. Medical history will be obtained, including diagnosis of primary disease  (date of 
diagnosis ), clinical stage and Gleason score (individual scores and sum) at diagnosis, 
presence , date  and extent of soft tissue and bone metastases, details and dates of 
primary treatment, and details and dates of prior therapies f or prostate cancer , 
concurrent illnesses and family history.  
4. The use of any medications will be recorded (including radiation). This will include 
medications currently being taken and those taken within the last 30 days. This will 
also include the type of androgen deprivation therapy (ADT) utilized and when it was 
initiated.  Over -the-counter (OTC) medications as well as medications taken on an as -
needed basis (PRN) should be recorded.  
5. Vital signs (temperature/pulse/supine blood pressure)  
6. Physical examinati on including height  and weight  
7. History of hot flash frequency and severity  
8. Thromboembolic  risk assessment  including : a) Factor V Leiden gene mutation ; b) 
Lupus Ant icoagulant assessment and Cardiolipin assessment ; c) Prothrombin gene 
mutation ; and Protein C and S.   
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 22 - NOTE: detection of lupus anticoagulant, cardiolipin antibody outside the normal 
range, p rolonged PTT -LA, dRVVT and Protein C and/or Protein S deficiency are not 
exclusionary from the study. However, if a patient has lupus anticoagulant de tected, 
cardiolipin outside the normal range, a prolonged PTT -LA, a prolonged dRVVT or is 
deficient for Protein C and/or Protein S, and remains eligible for participation in the 
study, prophylactic anticoagulation therapy should be considered.  
For Protein C or Protein S deficiency, consideration should be given to dietary 
changes to increase Vitamin K intake.  
9. Electrocardiogram - 12 lead (single)  
10. Caprini V enothromboembo lism (VTE) Risk Assessment  
NOTE: Caprini VTE Risk is not an inclusion/exclusion criteria for the study. It is 
iQWeQded WR aVVeVV Whe SaWieQW¶V RYeUall UiVk fRU VTE aQd Whe chaQge Rf UiVk RYeU Whe 
course of the study.  
11. Clinical Laboratory Tests  
x Hematology  (Appendix A)  
x Serum hormones  (Appendix A ) 
x Serum chemistry  (Appendix A ) 
x Urinalysis  
12. Measurement of frequency and severity of hot flashes utilizing electronic device 
(values over 14 contiguous days  in order to establish a weekly baseline ) 
x Must be at least 80% compliant  during this assessment .  This translates into 
recording frequency and severity of hot flashes at least 11 of the 14 days.  
 
13. Bilateral Doppler ultrasound of the lower extremity (If the subject is diagnosed with a 
VTE in this assessment, the subject will not  be eligible for the study under the 
exclusio n criterion of history of a VTE ). 
Patients that have been previously screened for this study and could not complete screening 
for reasons other than not meeting the inclusion and exclusion criteria, may be rescreened into 
the study. Laboratory testing conducted under this protocol (Appendi x A) within 45 days 
prior to randomization into this study, may be used as the baseline laboratory values for this 
study and repeat laboratory testing is not required unless new coadministered medication(s) 
has been started, unless the investigator determi nes that retesting is warranted.   
Patients that failed screening under previous versions of the protocol due to a positive lupus 
aQWicRagXlaQW, bXW iQ ZhRm lXSXV aQWicRagXlaQW ZaV QRW ³deWecWed´ ma\ be UeVcUeeQed XQdeU 
Amendment 2, Version 7.0 of the proto col. 
Patients that failed screening under previous versions of the protocol due to indeterminant 
cardiolipin antibody, may be rescreened under Amendment 2, Version 7.0 of the protocol.  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 23 - Patients that failed screening under previous versions of the protocol due a finding related to 
Protein C or Protein S, including patients that were excluded from participation 
inappropriately due to elevated levels of Protein S and/or Protein C above the upper limit of 
normal, may be rescreened under Amendment 2, Version 7.0  of the protocol.  
For patients that fall into the three categories outlined above, laboratory testing conducted 
under this protocol (Appendix A) within 45 days prior to randomization into this study, may 
be used as the baseline laboratory values for this s tudy and repeat  laboratory testing is not 
required unless new coadministered medication(s) has been started or if the investigator 
determines that retesting is warranted.  
 
8.3 Enrollment  
Subjects will be enrolled from 2 to 5 days prior to the Day 1 visit. Enro llment should be done 
after the subject has completed the screening assessments and after it has been determined 
that the subject meets all the inclusion and exclusion criteria.  
Assess eligibility status for inclusion into the trial based on protocol inclu sion/exclusion 
criteria, including results from screening lab assessments.  
8.4 Day 1 Visit  
Subjects should fast for at least 8 hours (overnight) prior to this visit.  The Day 1 visit  
assessments will se rve as the baseline assessments.  
1. The medical history shoul d be reviewed and updated to include any changes occurring 
since the screening visit.  
2. Assessment of eligibility  
3. Vital signs (temperature/pulse/supine blood pressure)  
4. Physical examination  (including weight)  
5. Hematology (Appendix A)  
6. Serum chemistry  (Appendix A ) 
7. Urinalysis  
8. Serum hormones  (Appendix A ) 
9. Bone turnover markers  (Appendix A ) 
10. Record the usage of any concomitant medications and ongoing treatments . 
11. Adverse events (ongoing on Day 1)  
12. Caprini VTE  Risk Assessment (Appendix D ) 
13. Blood sample s for pharm acokinetic assessment  
14. Assess  hot flashes  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 24 - 15. Dispense study drug 
16. First dose- Instruct the subject  to take his  capsule  at the same time each day 
8.5 Day 14 Visit  
The following assessments will be conducted on Day 14 (± 3 days) : 
1. Vital Signs  
2. Serum Chemistry ± (Appendix A)  
3. Record the usage of any concomitant medications and treatments  
4. Adverse events  
8.6 Day 30 and Day 60 Visit  
Subjects should fast for at least 8 hours (overnight) prior to these  visits. The following 
assessments will be conducted on Day 30  (± 7 days) and Day 60  (± 7 days): 
1. Vital Signs (temperature/pulse/supine blood pressure)  
2. Serum c hemistry ± (Appendix A ) 
3. Hematology  ± (Appendix A)  
4. Serum hormones ± (Appendix A ) 
5. Blood sample s for pharmacokinetic assessment  
6. Record the usage of any concomitant m edications and treatments . 
7. Assess hot flashes (see Appendix C ) 
8. Caprini Venothromboembo lism Risk Assessment (Appendix D ) 
x It is important to note that it is expected that the patient population included in this 
study will have some risk of VTE d ue to age, presence of a malignancy, and BMI. The 
purpose of this assessment is a change in risk from baseline. Also, while the 
questionnaire is designed for the patient to complete, in this study, the Caprini VTE 
risk assessment should be filled out by st udy personnel with information from the 
SaWieQW aQd SaWieQW¶V chaUW.   
If there is a n increase in risk from baseline (Day 1) in this assessment, appropriate 
preventative actions should be taken. The subject should be consulted about the risk 
for VTE and act ions that would increase their risk further such as long periods of 
inactivity and surgery. Prophylactic anticoagulation therapy should be considered.   
Prolonged PTT -LA, dRVVT  and Protein C and/or Protein S deficiency are not 
exclusionary from the study. However, if a patient has a prolonged PTT -LA, a 
prolonged dRVVT or is deficient for Protein C and/or Protein S, and remains eligible 
for participation in the study, prophylacti c anticoagulation therapy should be 
considered.  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 25 - For Protein C or Protein S deficiency, consideration should be given to dietary 
changes to increase Vitamin K intake.  
9. Adverse events  
10. Collect capsule bottles and perform capsule accountability/compliance asses sment  
11. Dispense study drug 
8.7 Day 84 Visit  (End of Study Visit)  
Subjects should fast for at least 8 hours (overnight) prior to th is visit. The following 
assessments will be conducted on Day  84 (± 7 days): 
1. Vital Signs (temperature/pulse/supine blood pressure)  
2. Physical examination (including weight)  
3. Serum c hemistry  (Appendix A) (central laboratory)  
4. Hematology  (Appendix A) (central laboratory)  
5. Serum hormones  (Appendix A)  (central laboratory)  
6. Blood sample s for pharmacokinetic assessment  
7. Bone turnover markers  
8. Record the usage of any concomitant m edications and treatments  
9. Adverse events  
10. Assess hot  flashes (see  Appendix C ) 
11. Caprini Venothromboembo lism Risk Assessment (Appendix D ) 
x It is important to note that it  is expected that the patient population included in this 
study will have some risk of VTE due to age, presence of a malignancy, and BMI. The 
purpose of this assessment is a change in risk from baseline. Also, while the 
questionnaire is designed for the pa tient to complete, in this study, the Caprini VTE 
risk assessment should be filled out by study personnel with information from the 
SaWieQW aQd SaWieQW¶V chaUW.  
If there is a n incre ase in risk from baseline (Day 1 ) in this assessment, appropriate 
preventat ive actions should be taken. The subject should be consulted about the risk 
for VTE and actions that would increase their risk further such as long periods of 
inactivity and surgery. Prophylactic anticoagulation therapy should be considered.  
12. Collect capsul e bottles and perform capsule accou ntability/compliance assessment  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 26 - 8.8 Follow -up Visit  
The following assessments will be performed 30 days (± 7 days) after the End of Study visit  
(Day 84) : 
1. Vital Signs (temperature/pulse/supine blood pressure)  
2. Physical examination (including height  and weight ) 
3. Adverse events  
8.9 Pharmacokinetic Sampling  
8.9.1 Blood Samples  
Samples of venous blood for the determination of trough plasma concentrations of VERU -944 
and related metabolite s will be obtained on Days 1 (prior to dose) , 30, 60 and 84. The sample 
should be taken prior to dosing with VERU -944 on these days. The time of the last dose of 
study drug prior to the clinic visit (day before visit) and the time of the blood  sample s should 
be carefully recorded.  
The blood  samples shou ld be collected in  a 6 mL K 2EDTA blood collection tube at each 
collection time .   
Immediately after collection, the tube s will be gently inverted several times to mix the 
anticoagulant with the blood sample. Blood samples may be kept on wet ice  (the use of ice 
packs in a water bath is also acceptable)  for up to 20 minutes until processed. The plasma 
fraction will be separate d by placing the collection tube into a centrifuge for 10 minutes at 
1,500 x g. The plasma fraction will be withdrawn by pipette and divided into two 
polypropylene freezing tubes (with each tube receiving approximately equal aliquots ). All 
plasma samples w ill be placed into a freezer at -20oC (or below) within 1 hour after 
collection . (NOTE: A flash freezing in dry ice or liquid nitrogen is NOT required under this 
protocol but may be used .) 
Any remaining plasma samples after completion of the protocol outli ned pharmacokinetic 
analysis may be used to identify and quantify the metabolites of VERU -944 or measure other 
biomarkers of safety or efficacy . 
8.9.2 Plasm a Sample L abels  
The plasma freezing tube labels will contain the following information:  
x Subject N umber  
x Study Number  
x Site Number  
x Nominal Day Collection  
x Aliquot Number: Aliquot A or B  
x Species and Matrix: Human Plasma  
x Sample Sequence Number  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 27 - x Barcode Number  
Labels will be fixed to freezing tubes in a manner that will prevent the label from be coming 
detached after freezing.    
All plasma samples will be stored frozen ( -20°C or below).   Details of the method validation 
and sample analysis will be included with the final report.  
8.10 Rules for Subjects that Become at High Risk for the Development of Venous 
Thromboembolic Events during the Study  
If a subject has any of the events  listed below  during the study, they are considered to have an 
increase d risk of development  of a VTE. T he subject should be monitored closely and 
prophylactic anticoagulation therapy  should be used if clinically indicated. These subjects are 
not required to discontinue the study if these events occur:  
1. Surgery  
2. Hospitalization  
3. Trauma , such as a broken long bone  
4. Radiation therapy to prostate for cancer control (radiation to bone to relie ve pain is 
acceptable)  
5. Prolonged immobilization  
If a subject is expecting to have a prolonged immobilization such as a long car ride or plane 
ride or sitting at a desk for a long period of time, the subject should be instructed carefully 
about proper steps  to take to prevent VTEs. Specifically, subjects should be instructed to, 
whenever possible , get up and walk around (at least every two hours) and flex your feet up 
and down while sitting by alternating raising your toes off the floor while keeping your he els 
on the floor and then pointing your toes. Subjects should also wear compression stockings if 
long periods of inactivity are expected.  
The Caprini Venothromboembolism Risk Assessment (Appendix E) rules and instructions 
should be followed. However, it is  important to note that it is expected that the patient 
population included in this study will have some risk of VTE due to age, presence of a 
malignancy, and BMI. The purpose of this assessment is to monitor for increased risk from 
baseline. The events li sted above will increase the risk of VTEs in these patients.  
8.11 Subject Stopping Rules  
If, in the opinion of the investigator, the participation in the study is or is becoming 
detrimental to the well -being of a particular subject, this issue should be discussed with the 
Medical Monitor for this study and dosing may be discontinued.  
Subjects that experience a Grade 3 or greater toxicity according to the Common Terminology 
Criteria for Adverse Events (CTCAE) version 4 
Veru Inc  CONFIDENT IAL
Protocol V72203  – FINAL Version 9.0 
FINAL: AMENDMENT 4 30 October  2019  - 28 - (https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf)  
that is deemed to be possible, probably or definitely related to study drug will be discontinued 
from the study . Prior to discontinuation from the study , the grading of the event and causal 
relationship should be discussed with the Medical Monitor for the study . 
Subjects will be discontinued from dosing if AST or ALT levels are >5 times the upp er limit 
of normal, or if AST or ALT levels are > 3 times the upper limit of normal  along with a total 
bilirubin elevation of >2 times the upper limit of normal . 
8.12 Early Discontinuation of Study Treatment  
A subject will be considered to have completed the trial if they received at least 84 days of 
treatment with VERU -944 or the study is terminated by the sponsor .  Subjects may 
prematurely discontinue study treatment for any of the following reasons:  
1.Consent Withdrawn ( specify the reason) .
2.Significant and unacceptable adverse event  ± specify the adverse event leading to
discontinuation
3.Investigator decision ( specify the reason), must be approved by the Medical Monitor
4.Non-compliance by subject with protocol requirements, must be approved by the Medical
Monitor
5.Lost to follow -up (record the date of last contact)
6.Death  (specify the following information)
a.Date of death
b.Death due to primary disease? Yes or no
c.Death due to study drug? Yes or no
d.Death due to adverse event? Yes or no
7.Study terminated by the Sponsor
8.Other reason (specif y the reason)  should be  approved by  the Medical Monitor
The reason for discontinuation of study treatment will be documented for each subject. 
Subjects who discontinue prematurely will not be replaced. If a subject is discontinued from 
the study, he will be asked to complete all End of Study  visit assessments  and return all study 
materials (s tudy medication and electronic device ). At the time of discontinuat ion, please fill 
out the End of Study  case report forms ( eCRF s) and subject disposition eCRF  pages.  
8.13 Adverse Events  
An adverse event (AE) is any unfavorable or unintended change in body structure (signs) or 
body function (symptoms), abnormal laboratory result that is associated with symptoms or 
requires treatment, or w orsening of a pre -existing condition. This includes all such events 
regardless of the presumed relationship between the event and the study medication(s).  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 29 - Any AE that occurs after the informed consent is signed but prior to dosing on Day 1 will be 
captured  as part of the medical history and will be documented on the appropriate eCRF . This 
would include AEs resulting from concurrent illnesses, reactions to concomitant medications 
or progressive disease states. These AEs will be captured as part of the medica l history.  
Each subject will be assessed for the development of any adverse event s. Adverse events 
should be assessed at each visit to the clinic. This information should be obtained in the form 
of non -leading questions (e.g., "How are you feeling?") and f rom signs and symptoms 
detected during each examination, observations of the study personnel or spontane ous reports 
from the subjects.  
Any AEs such as complaints, signs, or symptoms that occur during the course of the study or 
designated follow -up periods will be recorded on the subject's case report form  (eCRF ). This 
would include AEs resulting from concurrent illnesses, reactions to concomitant medications, 
or progressive disease states.  
Whenever possible, the AE will be described on the case report form using standard medical 
terminology consistent with Common Terminology Criteria for Adverse Events (CTCAE) 
version 4 in order to avoid the use of vague, ambiguous or colloquial expressions. The 
investigator will evaluate all adverse events as to their inten sity, relation to test medication, 
outcome and action taken.  
Each AE will be evaluated for duration, intensity, and relationship to (or association with) the 
study treatment (or other causes). Additionally, the actions taken (e.g., reduction of dosage, 
discontinuation of study medication, administration of treatment, etc.) and the resulting 
outcome of the AE will be indicated on the case report form.  
Any subject who is withdrawn from the study due to an adverse event  will be followed until 
the ou tcome of the event is determined, and the investigator will prepare a written summary 
of the event and document the available follow -up information on the case report form.  
8.13.1  Intensity of Adverse E vents 
The intensity of the AEs will be graded according to CTCAE version 4. For any adverse event 
that is not specifically covered in CTCAE version 4, the following criteria  should be used : 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 30 - Grade Description 
1 Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated 
2 Moderate; minimal, local or noninvasive intervention indicated; 
limiting age-appropriate instrumental activities of daily living 
3 Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living 
4 Life-threatening consequences; urgent intervention indicated. 
5 Death related to AE 
If the intensity (Grade) changes within a day, the maximum intensity (Grade) should  be 
recorded. If the intensity (Grade) changes over a longer period of time, the changes should be 
recorded as separate events (having separate onset and stop dates for each grade).  
8.13.2  Test M edication  Causality  
The relationship (or association) of each AE to the test medication will be assessed by the 
investigator according to the following definitions:  
Unrelated:  There is no chance that the study medication caused the AE; other conditions, 
including concurrent illnesses, progression or expression of the disea se state, or a reaction to a 
concomitant medication best explain the event.  
Unlikely:  There is little chance that the study medication caused the AE; other 
conditions, including concurrent illnesses, progression or expression of the disease state, or a 
reaction to a concomitant medication best explain the event.  
Possible:  The association of the AE with the study medication is unknown; however, the 
AE is not clearly due to another condition.  
Probable:  A reasonable temporal association exists between the AE and treatment 
administration and, based on the investigator's clinical experience, the association of the AE 
with the study treatment seems likely.  
Definite:  The association of the AE with the study medication has a direct relationship.  
For the purpose of safety analyses, all AEs which are classified as "Possible," "Probable" or 
³DefiQiWe´ Zill be cRQVideUed WUeaWmeQW -related events.  
Veru Inc  CONFIDENT IAL
Protocol V72203  – FINAL Version 9.0 
FINAL: AMENDMENT 4 30 October  2019  - 31 - 8.13.3  Serious Adverse E vents 
A serious adverse event  (SAE)  is defined as any experience that suggests a significant 
clinical hazard , contraindication, side effect, or precaution. This includes any event which:  
x Results in death.  
x Is life -threatening.  
x Requires inpatient hospitalization or causes prolongation of existing hospitalization  
x Results in persistent or significant disability/inca pacity.  
x Results in congenital abnormality/birth defect.  
x Requires intervention to prevent permanent impairment or damage  
An SAE also may include other events, based on medical judgment, which jeopardize the 
patient or subject and require medical or surgical intervention to prevent one of the outcomes 
listed above.  
Any SAE, including death due to any cause, which occurs during the study or within 30  days 
following cessation of study medication, whether or not related to the study medication, must 
be reported immediately via telephone (within 24  hours) to Veru Inc. Drug Safety . 
In addition, the investigator must immediately complete a Serious Adverse Event eCRF  report 
form and electronically submit the form.  The investigator will promptly notify the 
Institutional Review Board  (IRB). 
If additional information regarding a previously submitted SAE is obtained, a follow -up SAE  
eCRF  report should be completed and  submitted  as indicated above.  Supporting source 
documen tation should be provided to Worldwide Clinical Trials  Drug Safety at the contact 
information below.  
Worldwide Clinical Trials Drug Safety Contact Information : 
Fax number: 1-866-387-5539 or +44 (0) 115 922 0960  
E-mail: 
drugsafety@worldwide .com  
Worldwide Clinical Trials  Medical Monitor:  
Noor Khaskhely, MD, PhD  Sr. Medical Director , Medical Affairs Worldwide 
Clinical Trials  
Office +1 610 632 8151 Mobile +1 919 324 4351  
 noor.khaskhely@worldwide.com  
8.13.4  Initial Reports 
SAEs will be collected from the time of first stud y drug administration through 30  days after 
receipt of final dose of study drug.  SAEs and events of clinical interest must be reported to 
the Sponsor (or designee) within 24 hours of the knowledge of the occurre nce.  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 32 - In the event an SAE is observed or reported, the SAE report will be co mpleted as thoroughly 
as possible including all available details about the event and the signature of the Investigator. 
If the Investigator does not have all information about an SAE, the Investigator will not wait 
to receive additional information before  notifying the Sponsor of the event and completing the 
form. The form will be updated when additional information is received.  
8.13.5  Precautions  
Adverse event s should be treated in accordance with standard medical practice. During the 
course of the study, the o verall safety, tolerability and pharmacokinetics  of all study 
treatments will be reviewed by the sponsor and the investigator.  
8.13.6  Reporting of Adverse Events Associated with Study Drug Overdose, Misuse, 
Abuse or Medication Error  
AEs associated with study drug  overdose, misuse, abuse, and medication error refer to AEs 
associated with uses of the study drug outside of that specified by the protocol. Overdose, 
misuse, abuse, and medication error are defined as follows:  
Overdose: Accidental or intentional use of t he study drug in an amount higher than the 
protocol -defined dose  
Misuse:  Intentional and inappropriate use of study drug not in accordance with the protocol  
Abuse: Sporadic or persistent intentional excessive use of study drug accompanied by harmful 
physi cal or psychological effects  
Medication error: Any unintentional event that causes or leads to inappropriate study drug use 
or subject harm while the study drug is in the control of site personnel or the subject.  
All AEs associated with overdose, misuse, a buse, or medication error should be captured on 
the Adverse Event eCRF and also reported using the procedures detailed in Reporting of 
SAEs even if the AEs do not meet serious criteria. Abuse is always to be captured as an AE. If 
the AE associated with an overdose, misuse, abuse, or medication error does not meet serious 
criteria, it must still be reported using the SAE form and in an expedited manner but should be 
noted as non -serious on the SAE form and the Adverse Event eCRF.  
8.14 Concomitant  Medications  and Concomitant Therapies  
Any medication  (including OTC medications)  taken by a subject within 30 days prior to the 
Screening Visit and  during the course of the study and the reason for use of the medication 
will be recorded on the eCRF . Upon entering the stud y, each subject will be instructed to 
report the use of any medication (including OTC medications) to the investigator.  
Any radiation therapy (linear beam or seeds) taken by the subject within 30 days prior to the 
Screening Visit and during the course of t he study, including type of treatment, and duration 
of the treatment will be recorded on the eCRF . 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 33 - 8.15 Prohibited  Medications  
The following medications are prohibited  with the appropriate washout period, if any, for 
each prohibited medication:  
x All anabolic steroids and supplements containing anabolic steroids are prohibited from use 
during the study. This includes, but is not limited to , testosterone and testosterone -like 
compounds.  Use of anabolic steroids and supplements containing anabolic steroids >6 
months prior to screening  into the study is allowed.  
x Medroxyprogesterone acetate is prohibited from use during the study. Use of 
medroxyprogesterone >6 months prior to screening  into the study is allowed.  
x Clomiphene (Clomid® or a generic equivalent to Clomid) is prohibited from use during 
the study. Use of c lomiphene >6 months prior to screening  into the study is allowed.  
x Diethylstilbestrol and estrogen therapy are prohibited from use during the study.  Use of 
diethylstilbestrol and estrogen therapy >6 months prior to screening  into the study is 
allowed.  
x Initiation of treatment with selective serotonin reuptake inhibitors not allowed during the 
study and 6 months prior to the study is not allowed. However, if a patient is on stable 
sSSRI for >6 months  prior to screening  and is still qualifies for the study, thi s is allowed.  
x Cytotoxic chemotherapy is prohibited from use during the study.  
x Saw Palmetto , Black Cohosh, soy pills  and PC -SPES are prohibited from use during the 
study.  However, a washout period of >90 days  prior to screening  is allowed.  
x Gabapentin is prohibited from use during the study. A washout period of >60 days  from 
screening  is allowed.  
x Other experimental study medications  are prohibited from use during the study . A 
washout of > 90 days  prior to screening  is allowed.  
8.16 Withdrawal  of Subjects  
a. Any subject found to have entered the study in violation of the protocol will be 
withdrawn from the study.  
b. An effort must be made to determine why any subject discontinues the study 
prematurely. This information will be recorded on the case report  form.  
c. All subjects reserve the right to withdraw from the study at any time. The investigator 
will encourage all subjects who decide to withdraw from the study to complete all 
evaluations which may be necessary to assure that the subject is free of untowa rd effects 
and to seek appropriate follow -up for any continuing problems.  
d. Any subjects who develop a clinically significant medical condition, as judged by the 
investigator, so that the subject no longer meets the inclusion/ exclusion criteria . 
e. Any subject  who requires the use of an unacceptable concomitant medication will be 
withdrawn from the study.  
The investigator will withdraw any subject from the study if, in the investigator's opinion, it is 
not in the subject's best interest to continue . No subject that discontinues from the study for 
any reason will be replaced.  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 34 - The date the subject is withdrawn from the study and the reason for discontinuation will be 
recorded on the case report form. When a subject fails to return for scheduled study visits, the 
investigator will make a reasonable effort to contact the subject and determine why the 
subject failed to return. This information will be documented on the study records. When a 
subject is withdrawn from the study (regardless of the reason), all evaluation s required at the 
final s tudy visit should be performed.  
9.0 STATISTICAL ANALYSIS  
9.1 Sample  Size Calculation  
The proposed trial sample size, n=30 per  arm, total N= 90 in Stage 1 , is based on the mean 
change in hot flash frequency from baseline to Week 4  (Day 28) (the planned primary 
endpoint at the time of the original study design) . Other assumptions include: one -sided 
Į=0.10; ȕ=0. 10 (i.e., power=0.9), equal variances, the variance is equal t o the mean of the 
active arm, and a frequency in at least one treated arm that is 40% less than that of the placebo 
arm on Week  4 (Day 28). The same assumptions hold for Stage 2 as well with proposed trial 
sample size of n=30 per arm, N=60 in Stage 2.  Tot al enrollment if both stages are completed 
will be approximately N=150.    
All patients in screening at the time that the 90th patient is randomized into Stage 1 of the 
study that qualify for the study will be randomized into the study up to a maximum of 120 
patients (40 per arm) . In Stage 2, all patients in screening at the time the 60th patient is 
randomized into Stage 2 of the study that qualify for the study will be randomized into the 
study up to a maximum of 80 patients (40 per arm).   
9.2 Populations  
Intent-to-Treat (ITT) population:  All enrolled subjects who have taken at least one dose of 
study drug.  
Efficacy Evaluable  (EE) population:  All subjects in the ITT population who have 
analyzable baseline data and 12 weeks of hot flash data . Subjects must also be at least 80% 
compliant with taking study drug with no major protocol deviations, including no major 
inclusion/exclusion deviations . 
Efficacy Evaluable  Interim Analysis ( EEIA) population:  All subjects in the ITT 
population who have analyzable baseline data and 6 weeks of hot flash data . Subjects must 
also be at least 80% compliant with taking study drug with no major protocol deviations, 
including no major inclusion/exclusion de viations.  
Safety population: All subjects that receive at least one dose of study medication. The safety 
analyses will be conducted on this population.  
9.3 Efficacy Analyses  
The primary efficacy analyses will be a mong the EE (EEIA)  population .  The compar ison of 
percentage change in frequency  from baseline to Week 6 between the placebo arm and each 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 35 - of the 10 mg and 50 mg dose arms will be of primary interest  in Stage 1 . In Stage 2, the 
comparis on of percentage change in frequency from baseline to Week 6 between the placebo 
arm and the 100 mg dose arm will be of primary interest.    
Subjects will record events of hot  flashes (frequency and severity ) utilizing an application on 
an electronic device (i.e. smartphone). An example of t he specific que stions asked and 
definitions of severity are included in Appendix C  
9.3.1 Primary Analys es 
9.3.1.1  Hot Flash  Frequency , Week 6 (Day 42) 
Mixed model s repeated measures (MMRM) analyse s that incorporate , treatment, time, 
and the treatment*time interaction s will be the primary analytical method  for the 
percentage  change in the frequency of moderate to severe hot flashes .  The percentage  
change  from baseline  in frequ ency  of moderate to severe  hot flashes  in each active 
arm will be compared to the placebo arm at Week 6 (Day 42). The analysis will be 
handled in two ways within the MMRM framewor k: (1) the means analysis comparing 
the change from baseline to Week 6, and (2) the slope analysis comparing the rate of 
change from baseline to Week 6.  
 
The primary endpoint  in the study will be analyzed when the last patient reaches  Day 
42. However, the clinical site and patients will remain blinded through the completion 
of the Day 84 efficacy assessments and the follow up safety visits . 
Each VXbjecW¶V hRW flaVh fUeTXeQc\ will be summed on a weekly basis.  Becau se the 
MMRM is the primary analytical method, it will be possible to estimate Week 6 
changes from baseline by incorporating the preceding weeks ¶ daWa , e.g., Week 6 
estimates will incorporate data from baseline and Week 1 through Week 6.  Analyses 
will be performed for the  EE (EEIA)  populations.  
If the MMRM model does not converge or has poor fit, T-tests or non-parametric 
tests, if the data are deemed non -normally distributed,  will compare changes over time 
within (Paired T -test or Wilcoxon sign -rank test) an arm and between (T-test or 
Wilcoxon rank sum test) each active arm and the placebo arm , respectively.  
The Hochberg procedure (Hochberg Y, 1988) will be applied to control for the 
multiple comparisons associated with the comparisons between  the two dose arms and 
placebo  and the two different MMRM analyses (means, slope) in the primary analyse s 
of frequency  of hot flash es in Stage 1 . The analyses for Stage 2 will be treated 
similarly to address the multiplicity of the MMRM analyses .  Note that the placebo 
arm in Stage 2 comprises a cohort of subjects distinct from those placebo subjects that 
were enrolled during Stage 1.  
 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 36 - 9.3.2 Secondary Analyses  
9.3.2.1  Hot Flash  Frequency  (Weeks 4 , 8, 10 and 12)  and Severity  (Week s 4, 6, 8, 
10, and 12) 
Mixed models repeated measures (MMRM) analyses that incorporate , treatment, time, 
and treatment*time interactions will be the primary analytical method for the 
percentage change in both the frequency and severity  of moderate to severe hot 
flashes :  frequency (severity).  The percent age change from baseline in frequency 
(severity) of moderate to severe hot flashes in each active arm  will be compared to the 
placebo arm at Week 4 (Day 28), Week 8 (Day 56), Week 10 (Day 70), and Week 12 
(Day 84).  Each analysis will be handled in two ways within the MMRM framework, 
as described for the primary analysis above.  
Each VXbjecW¶V hRW flaVh fUe quency (severity) will be summed on a weekly basis. 
Because the  MMRM is the primary analytical method, it will be possible to estimate 
Week s 4, 8, 10, and  12 changes from baseline by incorporating the precedi Qg ZeekV¶ 
data, e.g., Week s 4, 8, 10, and  12 estimates will incorporate data from baseline and 
Week 1 through Week s 4, 8, 10, and  12. Analyses will be performed for the ITT and 
PP populations.  
If the MMRM model does not converge or has poor fit, T -tests or non -parametric 
tests, if the data are deemed non -normally distributed, will compare changes over time 
within (Paired T -test or Wilcoxon sign -rank test) an arm and between (T -test or 
Wilcoxon r ank sum test)  each active arm and the placebo arm, respectively.  
If the MMRM model does not converge or has poor fit, non -parametric tests will  
compare changes over time within (Wilcoxon sign -rank test) an arm and between  
(Wilcoxon rank sum test) active arms and the placebo arm, respectively.  
The Hochberg procedure (Hochberg Y, 1988) will be applied to control for the 
multiple comparisons associated with the comparisons between the two dose arms and 
placebo and the two different MMRM analyses in the analyses of frequency (severity) 
of hot flashes for Stage 1. The analyses for Stage 2 will be treated similarly to address 
the multiplicity of the two MMRM analyses.   Note that the placebo arm in Stage 2 
comprises a cohort of subjects distinct from those placebo subjects that were enrolled 
during Stage 1 .  
The severity of hot flash analysis will be the average severity at bas eline of only the 
moderate and severe hot flashes. The severity of hot flashes analysis at Weeks 4, 6, 8, 
10, and 12 will be the average severity of all hot flashes, i.e. mild, moderate, and 
severe hot flashes.  
 
See the Statistical Analysis Plan for the study for full and complete statistical analyses 
planned for the study.  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 37 - 9.3.2.2  Bone Turnover Markers  
Values at baseline and each  scheduled assessment  (Day 84) for each treatment group 
will be assessed. The mean, standard deviation, median, minimum, and maximum 
values will be summarized at each of these time poi nts. The percentage change from 
baseline to Day 84  will be summarized as well . This will be done for the ITT 
population . T-tests or non -parametric tests, if the data are deemed non -normally 
distributed, will compare changes over time within (Paired T -test or Wilcoxon sign -
rank test) an arm and between (T -test or Wilcoxon rank sum test)  each active arm and 
the placebo arm, respectively.   
9.3.3 Exploratory Analyses  
9.3.3.1  Serum PS A 
Values at baseline and each  scheduled assessment  (Days 30, 60, and 84) in each 
treatment group will be assessed. The mean, standard deviation, median, minimum, 
and maximum levels will be summarized at each of these time points. The percentage 
change from baseline to each time point will be summarized as well. This will be don e 
for the ITT  population. T-tests or non -parametric tests, if the data are deemed non -
normally distributed, will compare changes over time within (Paired T -test or 
Wilcoxon sign -rank test) an arm and between (T -test or Wilcoxon rank sum test) each 
active a rm and the placebo arm, respectively.   
9.3.3.2  Change in Serum Total and Free  Testosterone C oncen tration  
Values at baseline and each scheduled assessment (Days 30, 60, and 84) for each 
treatment group will be assessed. The mean, standard deviation, median, minimum, 
and maximum lab values will be summarized at each of these time points. The 
percentage change from baseline to each time point will be summarized as well. This 
will b e done for the ITT  population. T-tests or non -parametric tests, if the data are 
deemed non -normally distributed, will compare changes over time within (Paired T -
test or Wilcoxon sign -rank test) an arm and between (T -test or Wilcoxon rank sum 
test) each act ive arm and the placebo arm, respectively.  
9.3.3.3  Serum SHBG  
Values at baseline and each  scheduled assessment (Days 30, 60, and 84) for each 
treatment group will be assessed. The mean, standard deviation, median, minimum, 
and maximum lab values will be summarized at each of these time points. The 
percentage change from baseline to each time point will be summarized as well. This 
will be done for the ITT  population. T-tests or non -parametric tests, if the data are 
deemed non -normally distributed, will compare changes over time within (Paired T -
test or Wilcoxon sign -rank test) an arm and between (T -test or Wilcoxon rank sum 
test) each active arm and the placebo arm, respectively.    
9.3.3.4  Pharm acokinetic A ssessments  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 38 - VERU -944 trough concentrations will be determined in each subject and used to 
calculate the mean, median, standard deviation, coefficient of variation, maxima and 
minima within each arm of the trough levels of VERU -944. 
9.3.4 Safety Analysis  
The frequency of adverse eve nts (AEs) will be tabulated by MedDRA term and system 
organ class. The incidence of AEs and the maximum intensity and frequency of AEs 
will be summarized. A new  onset AE is defined as an AE that was not present prior to 
treatment with study medication but appeared following treatment, or was present at 
treatment initiation but worsened during treatment. An AE that was present at 
treatment initiation but resolved and then reappeared while the patient was on 
treatment is a new -onset AE (regardless of the inte nsity of the AE when the treatment 
was initiated).  
All laboratory  results, vital sign measurements, and other safety variables will be 
summarized using appropriate descriptive statistics. Changes from baseline will be 
computed and will be summarized using appropriate descriptive statistics.  
9.3.4.1  Data Safety Monitoring Board  
There will be no formal Data Monitoring Committee for this study. Safety data , 
including all SAEs, will be reviewed on an ongoing basis by a Safety Review Team 
comprised of the Medical Monito r, and representatives of the Sponsor. This Safety  
Review Team will meet at least monthly.  Additional ad hoc meetings will be 
scheduled if required to evaluate the safety and/or thromboembolic events further.     
10.0 ADMINISTRATION PROCEDURES  
10.1 Study Conduct and Compliance  
The study will be conducted in accordance with the Code of Federal Regulations (21 CFR 
parts 50, 54, 56, 312, and 314), which originates from the ethical principles laid down in the 
Declaration of Helsinki. Good Clinical Practices (GCPs) and the policies and procedures of 
the Sponsor and/or its authorized representative will also be followed. This clinical trial will 
be overseen and managed by a contract research organization (CRO) and the Sponsor. The 
CRO will be responsible for data management, data handling, statistical analysis, quality 
assurance and the final study report. The Sp onsor will be responsible for project management 
of the CRO and clinical monitoring.  
Sponsor Emergency Contact Info: 
K. Gary Barnette, Ph.D. 
Chief Scientific Officer Veru Inc. 
 
Cell: 919-426-3611 
 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 39 -  
Before initiating a trial, the Investigator/ Institution should have written and dated 
approval/favorable opinion from the Independent Ethics Committee (IEC)/IRB for the trial 
protocol/amendment(s), written informed consent form, any consent form updates, subject 
recruitment procedures ( e.g., advertisements), any written information to be provided to 
subjects and a statement from the IEC/IRB that they comply with GCP requirements. The 
IEC/IRB approval must identify the protocol version as well as the documents reviewed.  
After IEC/IRB approval, changes will require a formal amendment. Once the study has 
started, amendments should be made only in exceptional circumstances. Changes that do not 
affect subject safety or data integrity are classified as administrative changes and gen erally do 
not require ethical approval. If ethically relevant aspects are concerned, the IEC/IRB must be 
informed and, if necessary, approval sought prior to implementation. Ethical approval on 
administrative changes will be obtained if required by local/s ite IEC/IRB.  
10.2 Informed Consent  
Prior to study entry, the Investigator, or a person designated by the Investigator, will explain 
Whe QaWXUe, SXUSRVe, beQefiWV aQd UiVkV Rf SaUWiciSaWiRQ iQ Whe VWXd\ WR each VXbjecW, VXbjecW¶V 
legally acceptable representativ e or impartial witness. Written informed consent must be 
obtained prior to the subject entering  the study (before initiation of any study -related 
procedure and administration of the investigational medicinal product ( IMP). Sufficient time 
will be allowed t o discuss any q uestions raised by the subject.  
The Sponsor will provide a sample informed consent form. The final version controlled form 
must be agreed to by the Sponsor and the IEC/IRB and must contain all elements included in 
the sample form, in languag e Ueadil\ XQdeUVWRRd b\ Whe VXbjecW. Each VXbjecW¶V RUigiQal 
cRQVeQW fRUm, SeUVRQall\ VigQed aQd daWed b\ Whe VXbjecW RU b\ Whe VXbjecW¶V legall\ acceSWable 
representative, and by the person who conducted the informed consent discussion, will be 
retained b y the Investigator. The Investigator will supply all enrolled subjects with a copy of 
their signed informed consent.  
The consent form may need to be revised during the trial should important new information 
become available that may be relevant to the safe ty of the subject or as a result of protocol 
amendments. In this instance approval should always be given by the IEC/IRB. It is the 
IQYeVWigaWRU¶V UeVSRQVibiliW\ WR eQVXUe WhaW all VXbjecWV VXbVeTXeQWl\ eQWeUed iQWR Whe VWXd\ aQd 
those currently in the stu dy sign the amended form. This is documented in the same way as 
previously described. Subjects who have completed the study should be informed of any new 
information that may impact on their welfare/wellbeing.  
The Investigator should, with the consent of t he VXbjecW, iQfRUm Whe VXbjecW¶V SUimaU\ 
physician about their participation in the clinical trial.  
10.3 Protocol Amendments  
In the event that an amendment to this protocol is required, it  will be classified into one of the 
following three categories:  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 40 - x Non-Subst antial Amendments  aUe WhRVe WhaW aUe QRW cRQVideUed µVXbVWaQWial¶ (e.g. , 
administrative changes) and as such only need to be notified to the IECs/IRBs or 
Competent Authorities (CA) for information purposes.  
x Substantial Amendments  aUe WhRVe cRQVideUed µVXbV WaQWial¶ WR Whe cRQdXcW Rf Whe cliQical 
trial where they are likely to have a significant impact on:  
- the safety or physical or mental integrity of the subjects;  
- the scientific value of the trial;  
- the conduct or management of the trial; or  
- the quali ty or safety of the IMP used in the trial.  
Substantial amendments must be notified to the IECs/IRBs and CA. Prior to 
implementation, documented approval must be received from the IECs/IRBs. In the case 
Rf Whe CA iQ Whe EU membeU VWaWeV, aSSURYal RU µfaYRUa ble RSiQiRQ¶ caQ be aVVXmed if Whe 
CA has raised no grounds for non -acceptance during an allocated time period (to be 
cRQfiUmed ZiWh Whe SSRQVRU¶V RegXlaWRU\ AffaiUV (RA) UeSUeVeQWaWiYe) fRllRZiQg 
acknowledgment of receipt of a valid application to make a substantial amendment.  
x Urgent Amendments  are those that require urgent safety measures to protect the trial 
subjects from immediate hazard and as such may be implemented immediately by the 
Sponsor with subsequent IECs/IRBs and CA notification, forthwith.  
10.4 Protocol Deviations  
It is the responsibility of the Investigator and Sponsor to ensure compliance with the study 
protocol. When the protocol is not followed, it can put the safety of study subjects at risk as 
well as jeopardize the accuracy and reliability of the study results which could lead to a 
rejection of the data by regulatory authorities.  
All identified deviations from the protocol must be documented and reported to the Sponsor 
using the appropriate electronic form to be supplied by the Sponsor . Devi ations will be 
categorized into minor d eviations or major deviations; d efinitions and examples of deviations 
will be provided by the Sponsor . The Sponsor will be reviewing all deviations on an ongoing 
basis.  
10.5 Data Handling and Recordkeeping  
10.5.1  Data Handling  
Data will be recorded at the site on the eCRF  and reviewed by the clinical research associate 
(CRA) during monitoring visits. The CRA will verify data recorded in the EDC system with 
source documents. All corrections or changes made to any study data must be appropriately 
tracked in an audit trail in  the EDC system. An eCRF  will be considered complete when all 
missing, incorrect, and/or inconsistent data has been accounted for and electronically signed 
by the Investigator or assignee.  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 41 - Data will be processed using a validated computer system conforming  to regulatory 
requirements.  
10.5.2  Data Entry  
Data must be recorded using the EDC system as the study is in progress. All site personnel 
must log into the system using their secure user name and password in order to enter, review, 
or correct study data. These pr ocedures must comply with Title 21 of the Code of Federal 
Regulations (21  CFR Part 11) and other appropriate international regulations. All passwords 
will be strictly confidential.  
10.5.3  Medical Information Coding  
For medical information, the following thesauri will be used:  
x Latest version of MedDRA (version 18.1 or higher) for medical history and AEs, and  
x World Health Organization Drug Dictionary Enhanced (Sept. 2015 or later) for prior and 
concomitant medications.  
10.5.4  Data Validation  
Validation checks programmed wi thin the EDC system, as well as supplemental validation 
performed via review of the data, will be applied to the data in order to ensure accurate, 
consistent, and reliable data. Data identified as erroneous, or data that are missing, will be 
referred to th e site for resolution through data queries.  
The eCRF s must be reviewed and electronically signed by the Investigator in order to be 
considered complete.  
10.5.5  Record Keeping  
Records of subjects, source documents, monitoring visit logs, eCRF s, inventory of study 
drugs, regulatory documents, and other Sponsor correspondence pertaining to the study must 
be kept in the appropriate study files at the site. Source data is defined as all information in 
original records and certified copies of original records of clinica l findings, observations, or 
other activities in a clinical study necessary for the evaluation and reconstruction of the 
clinical study. Source data are contained in source documents (original records or certified 
copies). These records will be retained in  a secure file for the period as set forth in the Clinical 
Study Agreement. Prior to transfer or destruction of these records, the Sponsor must be 
notified in writing and be given the opportunity to further store such records.  
10.6 Data Quality  
Monitored eCRF s transferred from the investigational site to the assigned Data Management 
group will be reviewed (secondary monitoring) for completeness, consistency, legibility and 
protocol com pliance.  
Reasons should be given on the relevant eCRF  for any missing data an d other protocol 
deviations. Any electronic queries and items not adequately explained will require additional 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 42 - electronic manual queries to be raised to the Investigator by the monitor for 
clarification/correction. The Investigator must ensure that queries  are dealt with promptly. All 
data changes and clarifications can be viewed in the audit trail function of the eCRF . 
Clinical site personnel must make themselves available for any potential audit by the Sponsor 
or Sponsor representative and regulatory auth orities, such as, but not limited to , United States 
Food and Drug Administration. The clinical site personnel must be completely responsive and 
cooperative during these audits.  
10.7 Regulatory Approval  
AV UeTXiUed b\ lRcal UegXlaWiRQV, Whe SSRQVRU¶V RegXlaWRU\ Affairs group will ensure all legal 
regulatory aspects are covered , and obtain approval of the appropriate regulatory bodies, prior 
to study initiation in regions where an approval is required.  
10.8 Publication Policy  
The Sponsor encourages acknowledgement of a ll individuals/organizations involved in the 
funding or conduct of the study, including medical writers or statisticians subject to the 
consent of each individual and entity concerned, including acknowledgement of the Sponsor.  
The results of this study may  be published or communicated to scientific meetings by the 
Investigators involv ed in the study. For multicenter  studies, a plan for scientific publication 
and presentation of the results may be agreed and implemented by the study Investigators or a 
Steering Committee. The Sponsor requires that reasonable opportunity be given to review the 
content and conclusions of  any abstract, presentation, or paper before the material is 
submitted for publication or communicated. This condition also applies to any amendments 
that are subsequently requested by referees or journal editors. The Sponsor will undertake to 
comment on t he draft documents within the time period agreed in the contractual 
arrangements, including clinical trial agreements, governing the relationship between the 
SSRQVRU aQd aXWhRUV (RU Whe aXWhRU¶V iQVWiWXWiRQ). ReTXeVWed ameQdmeQWV Zill be iQcRUSRUaWed 
by th e author, provided they do not alter the scientific value of the material.  
If patentability would be adversely affected by publication, this will be delayed until (i)  a 
patent application is filed for the content of the publication in accordance with appli cable 
provisions of the clinical trial agreement concerned, (ii)  the Sponsor consents to the 
publication, or  (iii) the time period as may be agreed in the contractual arrangements, 
including clinical trial agreements, governing the relationship between the  Sponsor and 
aXWhRUV (RU aXWhRUV¶ iQVWiWXWiRQ) afWeU UeceiSW Rf Whe SURSRVed SXblicaWiRQ b\ Whe SSRQVRU, 
whichever of ( i), (ii) or (iii) occurs first.  
The author undertakes to reasonably consider the Sponsor's request for delay to the proposed 
publication should the Sponsor reasonably deem premature to publish the results obtained at 
the then stage of the study.  
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 43 - 10.9 Clinical Study Report  
A final clinical study report will be prepared according to the ICH guideline on structure and 
contents of clinical study reports. A final clinical study report will be prepared where any 
subject has signed informed consent, regardless of whether the trial  is completed or 
prematurely terminated. Where appropriate an abbreviated report may be prepared. The CSR 
will be in compliance with any applicable regulatory requirements, national laws in force and 
will be in English.  
10.10  Contractual and Financial Details  
The Investigator (and/or, as appropriate, the hospital/institution authorized representative) and 
the Sponsor will sign a clinical study agreement prior to the start of the study, outlining 
overall Sponsor and Investigator responsibilities in relation to the  study. Financial 
remuneration will cover the cost per included subject, based on the calculated costs of 
performing the study assessments and other activities in accordance with the protocol, and the 
specified terms of payment will be described in the con tract. The contract should describe 
whether costs for pharmacy, laboratory and other protocol -required services are being paid 
directly or indirectly.  
10.11  Insurance  and Indemnity  
The Sponsor will obtain Product Liability insurance providing coverage relating t o the clinical 
study and subjects participating therein.  
11.0 REFERENCES   
1. American Cancer Society. Cancer Facts & Figures 2017. Atlanta: American Cancer 
Society; 2017.  
2. Brosman S.  1995 Depo -Provera as a treatment for hot flashes in men on androgen 
ablation  therapy.  J Urol 153(4):448A . 
3. Djavan, B., Eastham, J., Gomella, L., Tombal, B., Taneja, S., Dianat, S.S., Kazzazi, A., 
Shore, N., Abrahamsson, P .-A., and Cheetham, P., et al. 2012 . Testosterone in prostate 
cancer: the Bethesda consensus. BJU International 110,  344-352. 
4. Eaton A, McGuire N.  1993  Cyproterone acetate in treatment of post -orchidectomy hot 
Flushes.  Lancet 2:1336 -1137 . 
5. Engstrom, C.A. (2008). Hot flashes in prostate cancer: state of the science. American 
journal of men's health 2, 122 -132. 
6. Evans ML, Pritts E, Vittinghoff E,  McClish K, Morgan KS, Jaffe RB. 2005  Obstet 
Gynecol. 105(1):161 -6. 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 44 - 7. Fitzpatrick, S.L., Berrodin, T.J., Jenkins, S.F., Sindoni, D.M., Deecher, D.C., and Frail, 
D.E. (1999). Effect of estrogen agonists and antagonists on in duction of progesterone 
receptor in a rat hypothalamic cell line. Endocrinology 140, 3928 -3937.  
8. Frisk J. (2010). Managing hot flushes in men after prostate cancer --a systematic review. 
Maturitas 65, 15-22. 
9. Gerber GS, Zagaja GP, Ray PS, Rukstalis DB.  2000  Transdermal estrogen in the 
treatment of hot flushes in men with prostate cancer.  Urology 55(1):97 -101. 
10. Glashan RW and Robinson MR.  1981  Cardiovascular complications in the treatment of 
prostatic carcinoma.   Br J Urol. 53(6):624 -627. 
11. Holzbei erlein JM, Castle E, Thrasher JB. 2004. Complications of Androgen Deprivation 
Therapy: Prevention and Treatment. Oncology  (Williston Park) . Mar;  18(3):303 -309, 
discussion 310, 315, 319 -321. 
12. Irani, J., Salomon, L., Oba, R., Bouchard, P., and Mottet, N. (2010). Efficacy of 
venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of 
vasomotor  hot flushes in men taking gonadotropin -releasing hormone analogues for 
prostate cancer: a double -blind, randomized  trial. The Lancet. Oncology 11, 147 -154. 
13. Isbarn H, Boccon -Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg 
CN, Studer UE .  2009.  Androgen deprivation therapy for the treatment of prostate 
cancer: consider both benefits and risks.   Eur. Urol. 55(1):62 -75. 
14. Kaminetsky, J., Werner, M., Fontenot, G., and Wiehle, R.D.  2013 . Oral enclomiphene 
citrate stimulates the endogenous produc tion of testosterone and sperm counts in men 
with low testosterone: comparison with testosterone gel. The journal of sexual medicine 
10, 1628 -1635  
15. Kaplan, M., and Mahon, S. (2014). Hot flash management: update of the evidence for 
patients with cancer. Clin ical journal of oncology nursing 18 Suppl , 59-67. 
16. Karling P, Hammar M, Varenhorst E. 1994. Prevalence and duration of hot flushes after 
surgical or medical castration in men with prostatic carcinoma. J Urol 152:1170 ±3.  
17. Larocca A, Cavallo F, Bringhen S, et al. 2012. Aspirin or enoxaparin 
thromboprophylaxis for patients with newly diagnosed multi ple myeloma treated with 
lenalidomide. Blood. Jan 26; 119(4):933 -939; quiz 1093. Epub 2011 Aug 11.  
18. Loprinzi CL, Dueck AC, Khoyratty BS, Barton DL, Jafar S, Rowland KM, Atherton PJ, 
Marsa GW, Knutson WH, Bearden JD, Kottschade L and Finch TR.  1999  A phase  III 
randomized, double -blind, placebo -controlled trial of gabapentin in the management of 
hot flashes in men (N00CB) .  Ann Oncol. 20(3): 542 -549. 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 45 - 19. Loprinzi CL, Michalak JC, Quella SK, et al.  1994 Megestrol acetate for the prevention 
of hot flashes.  N  Engl J Med 331(6):347 -352. 
20. Loprinzi CL, Quella SK, Sloan JA, et al.  1999 Preliminary data from a randomized 
evaluation of fluoxetine (Prozac) for treating hot flashes in breast cancer survivors.  Proc 
San Ant onio Breast Cancer Society . 
21. Loprinzi , C.L., Michalak, J.C., Quella, S.K., O'Fallon, J.R., Hatfield, A.K., Nelimark, 
R.A., Dose, A.M., Fischer, T., Johnson, C., and Klatt, N.E. (1994). Megestrol acetate for 
the prevention of hot flashes. The New England Journal of Medicine 331, 347 -352. 
22. Mense  SM, Remotti F, Bhan A, et al. 2008. Estrogen -induced breast cancer: alterations in 
breast morphology and oxidative stress as a function of estrogen exposure. Toxicol Appl 
Pharmacol. Oct:232(1):78 -85. Epub 2008 Jul 1.  
23. Moraska AR, Atherton PJ,  Szydlo DW, B arton DL, Stella PJ, Rowland KM, Schaefer 
PL, Krook J, Bearden JD and Loprinzi CL.  2010.  Gabapentin for the Management of 
Hot Flashes in Prostate Cancer Survivors: A Longitudinal Continuation Study ± NCCTG 
Trial N00CB .  J Support Oncol., 8(3):128 -132. 
24. Mürdter, T.E., Kerb, R., Turpeinen, M., Schroth, W., Ganchev, B., Böhmer, G.M., Igel, 
S., Schaeffeler, E., Zanger, U., and Brauch, H., et al. (2012). Genetic polymorphism of 
cytochrome P450 2D6 determines oestrogen receptor activity of the ma jor infertility drug 
clomiphene via its active metabolites. Hum. Mol. Genet. 21, 1145 -1154.  
25. National Comprehensive Cancer Network  (2016). NCCN Guidelines for Patients: 
Prostate Cancer (Fort Washington, PA).  
26. Roth A, Scher H.  1997 Sertraline relieves hot fl ashes secondary to medical castration as 
treatment of advanced prostate cancer.   Psychooncology 7:129 -132. 
27. Schow DA, Renfer LG, Rozanski TA, Thompson IM. Prevalence of hot flushes during 
and after neoadjuvant hormonal therapy for localized prostate cancer.  South Med 
J. 1998;91:855 ±857. 
28. Siegel R, Naishadham D, Jemal A. 2012. Cancer Statistics, 2012. CA Cancer J Clin . 
Jan-Feb; 62(1):10 -29. Epub 2012 Jan 4.  
29. Smith JA. 1994  A prospective comparison of treatments for symptomatic hot flushes 
following endocrine therapy for carcinoma of the prostate.   J Urol.  152(1):132 -134. 
30. Smith JA. 1996  Management of hot flushes due to endocrine therapy for prostate 
carcinoma.   Oncology (Wil lston Park) 10(9):1319 -1322.  
31. Smith, M.R., and Crawford, E.D. (2017). Side Effects of Androgen Deprivation Therapy.  
Veru Inc  CONFIDENT IAL
Protocol V72203  – FINAL Version 9.0 
FINAL: AMENDMENT 4 30 October  2019  - 46 - 32.Szutu, M., Morgan, D.J., McLeish, M., Phillipou, G., Blackman, G.L., Cox, L.W., and
Dollman , W. (1989). Pharmacokinetics of intravenous clomiphene isomers. Br. J Clin
Pharmacol. 27, 639 -640.
33. Turner, R.T., Evans, G.L., Sluka, J.P., Adrian, M.D., Bryant, H.U., Turner, C.H., and
Sato, M. (1998). Differential responses of estrogen target tissues in rats including bone to
clomiphene, enclomiphene, and zuclomiphene. Endocrinology 139, 3712 -3720.
34.Ulloa E.W., Salup, R., Patterson, S.G., and Jacobsen, P.B. (2009). Relationship between
hot flashes and distress in men receiving androgen deprivation therapy for prostate
cancer. Psycho -oncology 18, 598 -605.
35.Vitolins, M.Z., Griffin, L., Tomlinson, W.V., Vuky, J., Adams, P.T., Moose, D., Frizzell,
B., Lesser, G.J., Naughton, M., and Radford, J.E., JR, et al. (2013). Randomized trial to
assess the impact of venla faxine and soy protein on hot flashes and quality of life in men
with prostate cancer. Journal of clinical oncology : official journal of the American
Society of Clinical Oncology 31, 4092 -4098.
36.Hochberg, Y (1988).  A sharper Bonferroni procedure for multi ple tests of significance.
Biometrika 75(4), 800 -2.
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 47 - 12.0 APPENDICES  
12.1 Appendix A: Clinical Laboratory Tests  (central laboratory)  
Hematology:  Urinalysis:  
Hemoglobin  pH 
Hematocrit  Specific Gravity  
Red Blood Cell Count  Protein  
White Blood Cell Count  Glucose  
White Blood Cell Differential  Leucocytes  
Platelet Count  Nitrates  
Reticulocyte Count  Ketones  
 Blood  
³Serum Hormones´  Microscopic Examination (only if urinalysis 
results are abnormal)  
LH  
FSH  
Total testosterone ( LC-MS/MS)  Serum Chemistry:  
Free testosterone (LC-MS/MS)  Sodium  
Sex Hormone Binding Globulin  Potassium  
Serum PSA  Chloride  
 Bicarbonate  
 BUN  
Bone turnover markers  Creatinine  
C-telopeptide (CTX)  Calcium  
Bone specific alkaline phosphatase  Phosphorus  
 Total Protein  
 Albumin  
Thromboembolic Risk Assessment  Total Bilirubin  
Factor V Leiden gene mutation  SGOT (ALT)  
Antiphospholipid antibodies for Lupus  SGPT (AST)  
Anticoagulant and Anticardiolipin  Alkaline phosphatase  
Prothrombin gene mutation  LDH  
Protein C and S  GGT  
 Glucose  
 
  
 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 48 - 12.2 Appendix B:  Schedule of Study Evaluationse 
Day Screena  
Pre-
Randomiz
ation 
during 
screening 
period 1 14 30 60 84 
End of 
study Follow-up  
Informed Consent X        
Medical History X  X      
Assessment of Eligibility (For 
Screening visit capture history of hot 
flashes frequency and severity  X X X      
Physical Exam X  X    X X 
Vital signs X  X X X X X X 
12-lead ECG (single) X        
Clinical Laboratory Tests         
Hematology X  X  X X X  
Urinalysis X  X      
Serum Chemistry X  X X X X X  
Serum Hormones X  X  X X X  
Blood sample for pharmacokinetic 
assessmentc   X  X X X  
Bone turnover markers   X    X  
Thromboembolic risk assessment X        
Bilateral Doppler ultrasound of the 
lower extremities  X       
Assess hot flashes (electronic diaries)  X X  X X X  
First dose   X      
Dispense study drug   X  X X   
Collect capsule bottles (even if 
empty) and perform 
accountability/compliance 
assessment b     X X X  
Assessment of conmeds X  X X X X X  
Assessment of AEs   X X X X X X 
Caprini VTE risk assessment d X  X  X X X  
a Screening evaluations to be conducted within 28 days prior to Day 1.  
b. Collect capsule bottles (even if empty) and perform accountability/compliance asse ssment throughout the participation of the subject in the 
study.  
c.  The pharmacokinetic blood sample s should be done prior to receiving the dose of study drug for that day.  
d.  It is important to note that it is expected that the patient population included in this study will have some risk of VTE due  to age, presence of a 
malignancy, and BMI. The purpose of this assessment is a change in risk from baseline.  Also, while the questionnaire is designed for the 
patient to complete, in this study, the Caprini VTE risk assessment should be filled out by study personnel with information from the patient 
and SaWieQW¶V chaUW.  
e. The same schedule of study evaluations will be used in Stage 1 and Stage 2 of this protocol.
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 49 - 11.3 Appendix C: Hot Flash Assessments  
Assessment s of hot flashes will be made at baseline ( 14 contiguous days during screening ) 
and daily from Day 1 (first dose) to the end of the study . Patients will record frequency 
and severity of hot flashes usi ng an electronic diary (eDiary)  to ensure attributable , time 
stamped data collection in an unsupervised environment.   When experiencing a hot flash 
the subject will indicate on the app that they have had a hot flash and then will assign a 
severity to the hot flash based upon the following scale:  
A. MILD :  sen sation of heat without sweating  
B. MODERATE :  sensation of heat with sweating, able to continue activity  
C. SEVERE :  sensation of heat with sweating, causing cessation of activity  
 
The hot flashes will then be  compiled to examine the number of hot flashes durin g the 
period and their severity.  
 
Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 50 - 12.3 Appendix  D: Caprini Venous Thromboemboli sm Risk  Factor  Assessment  
 
 

Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 51 -  
PROTOCOL SIGNATURE PAGE  
 
Protocol Number:  V72203  
Protocol  Date:  FINAL / 09 July 2018  
 AMENDMENT 1 FINAL / 29 October 2018  
 AMENDMENT 2 FINAL /17 January 2019  
 AMENDMENT 3 FINAL /22 February 2019  
 AMENDMENT 4 FINAL /30 October 2019  
Protocol Title:   
Randomized, double -blind, placebo controlled , dose finding Phase 2 
study comparing oral daily dosing of VERU -944 after a week of 
loading (daily dosing) with placebo to ameliorate the vasomotor 
symptoms resulting from androgen deprivation therapy in men with 
advanced prostate cancer  
   
 
 
 
SIGNATURE:  
   
Sponsor   Date 
  
Name and Title of Sponsor Representative   
 
 
This signature of the Sponsor Representative constitutes approval of this protocol.  
  

Veru Inc  CONFIDENT IAL 
Protocol V72203  – FINAL Version 9.0 
 FINAL: AMENDMENT 4 30 October  2019  - 52 -  
PRINCIPAL INVESTIGATOR SIGNATURE PAGE  
 
Protocol Number:  V72203  
Protocol Title:  Randomized, double -blind, placebo controlled , dose finding Phase 2 
study comparing oral daily dosing of VERU -944 aft er a week of 
loading (daily dosing) with placebo to ameliorate the vasomotor 
symptoms resulting from androgen deprivation therapy in men wit h 
advanced prostate cancer  
Protocol Date:   FINAL / 09 July  2018  
 AMENDMENT 1 FINAL / 29 October 2018  
 AMENDMENT 2 FINAL /17 January 2019  
 AMENDMENT 3 FINAL /22 February 2019  
 AMENDMENT 4 FINAL /30 October 2019  
SIGNATURE:  
 
   
Principal Investigator :  Date 
  
Name of Principal Investigator (Please Print)   
 
  
Address of Principal Investigator  
 
The signature of the Principal Investigator constitutes approval of this protocol and an 
assurance that this study will be conducted according to all requirements of this protocol 
and according to Good Clinical Practices (GCP).  